Document:

EX-10.8

 Exhibit 10.8 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

THE NATIONAL INSTITUTES OF HEALTH 

PATENT LICENSE AGREEMENT - EXCLUSIVE 

COVER PAGE 
 For the NIH internal use
only: 
 License Number: L-164-2013/0 

License Application Number: A-098-2012 

Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

[***] 
 Licensee: 

Aura Biosciences, Inc. 85 Bolton Street Cambridge, MA 02140 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A 

Additional Remarks: 
 Public
Benefit(s): The treatment, diagnosis and imaging of cancer tumors and metastases as well as their respective pre-cursor dysplasia states. 

This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a
Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty
Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are: 
  

	 	1)	 The National Institutes of Health (“NIH”), an agency of the United States Public Health
Service within the Department of Health and Human Services (“HHS”); and 

  

	 	2)	 The person, corporation, or institution identified above or on the Signature Page, having offices at the
address indicated on the Signature Page, hereinafter referred to as the “Licensee”. 

 The NIH and the Licensee
agree as follows: 
  

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the NIH or the FDA investigators made
inventions that may have commercial applicability. 

  

	 	1.2	 By assignment of rights from NIH or FDA employees and other inventors, HHS, on behalf of
the Government, owns intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assigned inventions. HHS also owns any tangible embodiments of these inventions actually
reduced to practice by the NIH of the FDA. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 1 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	1.3	 The Secretary of HHS has delegated to the NIH the authority to enter into this Agreement
for the licensing of rights to these inventions. 

  

	 	1.4	 The NIH desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Affiliate(s)” means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation
or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.2	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.3	 “Commercial Development Plan” means the written commercialization plan attached as
Appendix E. 

  

	 	2.4	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.5	 “FDA” means the Food and Drug Administration. 

 

	 	2.6	 “First Commercial Sale” means the initial transfer by or on behalf of the Licensee
or its sublicensees of the Licensed Products or the initial practice of a Licensed Process by or on behalf of the Licensee or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the
purpose of determining Net Sales. 

  

	 	2.7	 “Government” means the Government of the United States of America.

  

	 	2.8	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  

	 	2.9	 “Licensed Patent Rights” shall mean: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.9(a): 

  

	 	(i)	 continuations-in-part of
2.9(a); 

  

	 	(ii)	 all divisions and continuations of these
continuations-in-part; 

  

	 	(iii)	 all patents issuing from these
continuations-in-part, divisions, and continuations; 

  

	 	(iv)	 priority patent application(s) of 2.9(a); and 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 2 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

 

	 	(c)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.9(a): all counterpart foreign and U.S. patent applications and patents to 2.9(a) and 2.9(b), including those listed in Appendix A; and 

  

	 	(d)	 Licensed Patent Rights shall not include 2.9(b) or 2.9(c) to the extent that they contain one or
more claims directed to new matter which is not the subject matter disclosed in 2.9(a). 

  

	 	2.10	 “Licensed Processes” means processes which, in the course of being practiced, would be within
the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

 

	 	2.11	 “Licensed Products” means tangible materials which, in the course of manufacture, use, sale,
or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  

	 	2.12	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.13	 “Net Sales” means [***] 

 

	 	2.14	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

  

	 	2.15	 “Research License” means a nontransferable, nonexclusive license to make and to use the
Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

 

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The NIH hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use. 

  

	 	3.2	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the NIH other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	4.	 SUBLICENSING 

  

	 	4.1	 Upon written approval, which shall include prior review of any sublicense agreement by the NIH and which
shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights. 

  

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the NIH
of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be binding upon the sublicensee as if it were a party to this
Agreement. The Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 3 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the NIH, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to the NIH approval and contingent upon acceptance by the
sublicensee of the remaining provisions of this Agreement. 

  

	 	4.4	 The Licensee agrees to forward to the NIH a complete copy of each fully executed sublicense
agreement postmarked within [***] of the execution of the agreement. To the extent permitted by law, the NIH agrees to maintain each sublicense agreement in confidence. 

 

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

			
	 5.1
	 	 (a)   the NIH reserves on behalf of the Government an irrevocable,
nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or
international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory. Prior to the First Commercial Sale, the Licensee agrees to provide the NIH with reasonable
quantities of the Licensed Products or materials made through the Licensed Processes for NIH research use; and

  

	 	(b)	 in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(l)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights
or have the Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial
information that is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First
Commercial Sale, the Licensee agrees to provide the NIH with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for NIH research use. 

 

	 	5.2	 The Licensee agrees that products used or sold in the United States embodying the Licensed Products
or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the NIH. 

 

	 	5.3	 The Licensee acknowledges that the NIH may enter into future CRADAs under the Federal
Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the NIH when acquiring
these rights is necessary in order to make a CRADA project feasible. The Licensee may request an opportunity to join as a party to the proposed CRADA. 

 

			
	 5.4
	 	 (a)   in addition to the reserved license of Paragraph 5.1, the NIH
reserves the right to grant Research Licenses directly or to require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether
conducted at an academic or corporate facility. In order to safeguard the Licensed Patent Rights, however, the NIH shall consult with the Licensee before granting to commercial entities a Research License or providing to
them research samples of materials made through the Licensed Processes; and

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 4 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	(b)	 in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions
made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(T)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to
use the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license
itself. The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; o 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§3710a(c)(4)(B); and 

  

	 	(c)	 the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal
and judicial review under 35 U.S.C. §203(b). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the NIH a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the NIH a nonrefundable minimum annual royalty as set forth in
Appendix C. 

  

	 	6.3	 The Licensee agrees to pay the NIH earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the NIH benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the NIH sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the
Licensed Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses, or 

 

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

  

	 	6.7	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.8	 On sales of the Licensed Products by the Licensee to sublicensees or on sales made in other than
an arms-length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arms-length transaction, based on sales of like quantity and quality products on or
about the time of this transaction. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 5 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	6.9	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIH prior to the effective date of this Agreement, the Licensee shall pay the NIH, as an additional royalty, within
sixty (60) days of the NIH’s submission of a statement and request for payment to the Licensee, an amount equivalent to [***] of these unreimbursed expenses previously paid by the NIH, [***] of the remaining balance due
ninety (90) days from the NIH’s initial submission of a statement and request for payment and the remaining balance (i.e. [***] due One Hundred Twenty (120) days from the NIH’s initial submission of a statement and
request for payment. 

  

	 	6.10	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIH on or after the effective date of this Agreement, the NIH, at its sole option, may require the Licensee;

 [***] 
  

	 	6.11	 The NIH agrees, upon written request, to provide the Licensee with summaries of patent
prosecution invoices for which the NIH has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the NIH related to patent prosecution costs shall be
treated as confidential commercial information and shall not be released to a third party except as required by law or a court of competent jurisdiction. 

  

	 	6.12	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon ninety (90) days written notice to the NIH and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after ninety (90) days of the effective
date of the written notice. 

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, the NIH agrees to take responsibility for, but to
consult with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents to
the Licensee. 

  

	 	7.2	 Upon the NIH’s written request, the Licensee shall assume the responsibility for the
preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the NIH.
In this event, the Licensee shall, subject to the prior approval of the NIH, select registered patent attorneys or patent agents to provide these services on behalf of the Licensee and the NIH. The NIH shall provide
appropriate powers of attorney and other documents necessary to undertake this action to the patent attorneys or patent agents providing these services. The Licensee and its attorneys or agents shall consult with the NIH in all aspects
of the preparation, filing, prosecution and maintenance of patent applications and patents included within the Licensed Patent Rights and shall provide the NIH sufficient opportunity to comment on any document that the Licensee
intends to file or to cause to be filed with the relevant intellectual property or patent office. 

  

	 	7.3	 At any time, the NIH may provide the Licensee with written notice that the NIH wishes to
assume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights. If the NIH elects to reassume these responsibilities, the Licensee
agrees to cooperate fully with the NIH, its attorneys, and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and to provide the
NIH with complete copies of any and all documents or other materials that the NIH deems necessary to undertake such responsibilities. The Licensee shall be responsible for all costs associated with transferring patent
prosecution responsibilities to an attorney or agent of the NIH’s choice. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 6 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	7.4	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent Rights,
which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used,
sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the NIH. These records shall be retained for at least five (5) years following a given
reporting period and shall be available during normal business hours for inspection, at the expense of the NIH, by an accountant or other designated auditor selected by the NIH for the sole purpose of verifying reports and royalty payments
hereunder. The accountant or auditor shall be required to execute s a reasonable confidentiality agreement with Licensee, and shall only disclose to the NIH information relating to the accuracy of reports and royalty payments made under this
Agreement. If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then the Licensee shall reimburse the NIH for the reasonable cost of the inspection
at the time the Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within sixty (60) days of the date the NIH
provides to the Licensee notice of the payment due. 

  

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the NIH with the Commercial
Development Plan in Appendix E, under which the Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated
by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

  

	 	9.2	 The Licensee shall provide written annual reports on [***] for each of the Licensed Fields of Use
within [***]. These progress reports shall include, but not be limited to: [***]. The NIH also encourages these reports to include information on any of the Licensee’s public service activities that relate to the Licensed
Patent Rights. [***], the Licensee shall [***]. In the annual report, the Licensee may [***]. The Licensee agrees to provide any additional information reasonably required by the NIH to evaluate the
Licensee’s performance under this Agreement. The Licensee may amend the Benchmarks at any time upon written approval by the NIH. The NIH shall not unreasonably withhold approval of any request of the
Licensee to [***]. 

  

	 	9.3	 The Licensee shall report to the NIH the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such occurrences. 

  

	 	9.4	 The Licensee shall submit to the NIH, within [***] after each calendar half-year ending
June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf
of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, the Licensee shall submit payment of earned royalties due. If no earned
royalties are due to the NIH for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the Licensee [***]. The royalty report shall also identify the site
of manufacture for the Licensed Product(s) sold in the United States. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 7 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	9.5	 The Licensee agrees to forward semi-annually to the NIH a copy of these reports received by the
Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the NIH by the Licensee for activities under the sublicense. 

 

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the NIH at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. 

  

	 	9.8	 Additional royalties may be assessed by the NIH on any payment that is more than ninety (90) days overdue
at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the NIH of the overdue payment and additional royalties. The payment of any
additional royalties shall not prevent the NIH from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee
shall, to the extent permitted by law, be treated by the NIH as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the NIH under the
Freedom of Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d). 

 

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include reasonable adherence to the Commercial Development Plan in Appendix E and performance of the
Benchmarks in Appendix D. The efforts of a sublicensee shall be considered the efforts of the Licensee. 

  

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to use reasonable commercial efforts to
make reasonable quantities of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed Products.

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 8 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	10.5	 The Licensee agrees to supply, to the Mailing Address for Agreement Notices indicated on the
Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or the Licensed Processes or their packaging for educational and display purposes only. 

 

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 The NIH and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

 

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that the
NIH and appropriate Government authorities shall have the first right to take such actions; and 

  

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify the
NIH in writing. If the NIH does not notify the Licensee of its intent to pursue legal action within ninety (90) days, the Licensee shall be free to initiate suit. The NIH shall have a continuing right to
intervene in the suit. The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee may request the Government to initiate or join in any suit
if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit, the Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the
motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and progress of any litigation.
Before the Licensee commences an infringement action, the Licensee shall notify the NIH and give careful consideration to the views of the NIH and to any potential effects of the litigation on the public health in
deciding whether to bring suit. 

  

	 	11.3	 In the event that a declaratory judgment action alleging invalidity or
non-infringement of any of the Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the
Licensee under Paragraph 11.2, pursuant to this Agreement and the provisions of 35 U.S.C. Part 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided,
however, that the NIH and appropriate Government authorities shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 9 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	(d)	 if the NIH does not notify the Licensee of its intent to respond to the legal action within a
reasonable time, the Licensee shall be free to do so. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the Government
to initiate or to join any suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit by motion or any other action of the Licensee, the Licensee shall reimburse the Government
for any costs, expenses, or fees, which the Government incurs as a result of the motion or other action. If the Licensee elects not to defend against the declaratory judgment action, the NIH, at its option, may do so at its own
expense. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the NIH
and give careful consideration to the views of the NIH and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

 

	 	11.4	 In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and
disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee through court judgment or settlement shall be treated as Net Sales and subject to earned royalties. 

 

	 	11.5	 The NIH shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The NIH agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The NIH offers no warranties other than those specified in Article 1. 

 

	 	12.2	 The NIH does not warrant the validity of the Licensed Patent Rights and makes no representations
whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

 

	 	12.3	 THE NIH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	 The NIH does not represent that it shall commence legal actions against third parties infringing the
Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the NIH, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of: 

 

	 	(a)	 the use by or on behalf of the Licensee, its sublicensees, directors, employees, or third parties of any
Licensed Patent Rights; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or materials
by the Licensee, or other products or processes developed in connection with or arising out of the Licensed Patent Rights. 

  

	 	12.6	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 10 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not
fulfilled, and shall extend to the expiration of the last to expire of the Licensed Patent Rights unless sooner terminated as provided in this Article 13. 

 

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the NIH may terminate this
Agreement by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act. 

  

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify the NIH in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving the NIH sixty (60) days written notice to that effect. 

  

	 	13.5	 The NIH shall specifically have the right to terminate or modify, at its option, this Agreement,
if the NIH determines that the Licensee: 

  

	 	(a)	 is not executing the Commercial Development Plan submitted with its request for a license and the
Licensee cannot otherwise demonstrate to the NIH’s satisfaction that the Licensee has taken, or can be expected to take within a reasonable time, effective steps to achieve the Practical Application of the
Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not achieved the Benchmarks as may be modified under Paragraph 9.2; 

 

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

	 	(e)	 is not keeping the Licensed Products or the Licensed Processes reasonably available to the public
after commercial use commences; 

  

	 	(f)	 cannot reasonably satisfy unmet health and safety needs; or 

 

	 	(g)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived. 

  

	 	13.6	 In making the determination referenced in Paragraph 13.5, the NIH shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, the NIH shall give written notice to the Licensee providing the Licensee specific notice of, and a [***] opportunity to respond to, the NIH’s concerns as to the items referenced in 13.5(a)-13.5(g). If the Licensee fails to alleviate the NIH’s concerns as to the items referenced in 13.5(a)-13.5(g) or fails to initiate corrective action
to the NIH’s satisfaction, the NIH may terminate this Agreement. 

  

	 	13.7	 When the public health and safety so require, and after written notice to the Licensee providing the
Licensee a [***] opportunity to respond, the NIH shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 11 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	
under the Licensed Patent Rights, unless the Licensee can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of
the subject matter of the Licensed Patent Rights. The NIH shall not require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the Licensee. 

 

	 	13.8	 The NIH reserves the right according to 35 U.S.C. 5209(d)(3) to terminate or modify this
Agreement if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
Licensee. 

  

	 	13.9	 Within thirty (30) days of receipt of written notice of the NIH’s unilateral decision to
modify or terminate this Agreement, the Licensee may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated NIH official. The decision of the designated the
NIH official shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be accessible. 

 

	 	13.10	 Within ninety (90) days of expiration or termination of this Agreement under this Article 13, a
final report shall be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the NIH shall become immediately
due and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the NIH pursuant to Paragraph 4.3. Unless otherwise specifically provided for
under this Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products or other materials included within the Licensed Patent Rights to the NIH or provide the
NIH with certification of the destruction thereof. The Licensee may not be granted additional NIH licenses if the final reporting requirement is not fulfilled. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of the Government to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by the Government or excuse a similar subsequent
failure to perform any of these terms or conditions by the Licensee. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this Agreement
shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement. 

 

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be given by prepaid, first
class, registered or certified mail or by an express/overnight delivery service provided by a 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 12 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	
commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be designated in writing by the other party.
Agreement notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial
carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.

  

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to the Licensee’s Affiliate(s) without the prior written consent of the NIH. The parties agree that the
identity of the parties is material to the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the event that the NIH approves a proposed assignment, the Licensee shall pay the
NIH, as an additional royalty, one percent (1%) of the fair market value of any consideration received for any assignment of this Agreement within sixty (60) days of the assignment. 

 

	 	14.8	 The Licensee agrees in its use of any NIH-supplied materials to
comply with all applicable statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The Licensee agrees not to use the materials for research involving human subjects or clinical trials in the United States
without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the NIH, in
writing, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the NIH of research involving human subjects or clinical trials outside of the United States
shall be given no later than sixty (60) days prior to commencement of the research or trials. 

  

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of
these items may require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. The
NIH neither represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to mark the Licensed Products or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All the Licensed Products manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve the NIH’s
patent rights in those countries. 

  

	 	14.11	 By entering into this Agreement, the NIH does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
NIH, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the NIH, the FDA or the HHS or the Government or their employees
in any advertising, promotional, or sales literature without the prior written approval of the NIH. 

  

	 	14.12	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated the NIH official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available. 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 13 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the
source of the grant. 

  

	 	14.14	 Any formal recordation of this Agreement required by the laws of any Licensed Territory as a
prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the NIH. 

  

	 	14.15	 Paragraphs 4.3, 8.1, 9.5-9.8,
12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of this Agreement shall survive termination of this Agreement. 

  

	 	14.16	 The terms and conditions of this Agreement shall, at the NIH’s sole option, be considered by
the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee
and a fully executed original is received by the NIH within sixty (60) days from the date of the NIH’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 14 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 NIH PATENT LICENSE AGREEMENT -EXCLUSIVE 

SIGNATURE PAGE 
 For the NIH: 

 

							
	 /s/ Richard U. Rodriguez
	 		  	 8/28/13
	  	
	 Richard U. Rodriguez
 Director, Division of
Technology Development and Transfer
 Office of Technology Transfer

National Institutes of Health
	 		  	Date                    	  	

 Mailing Address or E-mail Address
for Agreement notices and reports: 
  

			
	 Chief, Monitoring & Enforcement Branch

Office of Technology Transfer
 National Institutes of Health

6011 Executive Boulevard, Suite 325
 Rockville, Maryland
20852-3804 U.S.A.
  

E-mail: LicenseNotices_Reports@mail.nih.gov
	  	

 For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any
statements of the Licensee made or referred to in this document are truthful and accurate.): 
 by: 

 

							
	 /s/ Elisabet de los Pinos
	 		  	 9/3/13
	  	
	Signature of Authorized Official	 		  	Date                    	  	
				
	 Elisabet de los Pinos, PhD
	 		  		  	
	Printed Name	 		  		  	
				
	 Founder & CEO
	 		  		  	
	Title	 		  		  	

  

					
	I.    	  	 Official and Mailing Address for Agreement notices:
	  	
			
		  	 Peter Finn.(Rubin & Rudman LLP)
	  	
		  	 Name
	  	
			
		  	 Counsel for Aura Biosciences
	  	
		  	 Title
	  	
			
		  	 Mailing Address
	  	
			
		  	 50 Rowes Wharf
	  	
			
		  	 Boston, MA 02110
	  	
			
		  	  
	  	
			
		  	  
	  	

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 15 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

							
		  	Email Address:	  	pfinn@rubinrudman.com                                  
          	  	
				
	     
	  	Phone:	  	[***]                                     
                                       	  	
				
		  	Fax:	  	[***]                                     
                                       	  	

  

					
	II.	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments)
			
		  	 Elisabet de los Pinos, PhD
	  	
		  	Name	  	
			
		  	 Founder & CEO
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge, MA 02140
	  	

  

							
		  	Email Address:	  	[***]                                     
                                       	  	
				
		  	Phone:	  	[***]                                     
                                       	  	
				
	    	  	Fax:	  	[***]                                     
                                       	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C.
§§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 16 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX A - PATENT(S) OR PATENT APPLICATION(S) 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 17 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 18 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX C - ROYALTIES 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 19 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX D - BENCHMARKS AND PERFORMANCE 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 20 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX E - COMMERCIAL DEVELOPMENT PLAN 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 21 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX F - EXAMPLE ROYALTY REPORT 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 22 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 APPENDIX G - ROYALTY PAYMENT OPTIONS 

[***] 

  

									
	 CONFIDENTIAL
	 				 		  	
	 NIH Patent License Agreement – Exclusive
	 				 		  	
	 Model 10-2005 (updated 8-2012) Page 23 of 31
	 	 	[Final	] 	 	[Aura Biosciences]	  	[August 20, 2013]

 NATIONAL INSTITUTES OF HEALTH 

FIRST AMENDMENT TO L-164-2013/0 

This is the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”)
within the Department of Health and Human Services (“HHS”), and Aura Biosciences, Inc. having an effective date of September 3, 2013 and having NIH Reference Number L-164-2013/0 (“Agreement”). This First Amendment, having NIH Reference Number L-l64-2013/1, is
made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852- 3804, U.S.A., and Aura Biosciences, Inc. having an office at 85 Bolton Street,
Cambridge, MA 02140 the (“Licensee”). This First Amendment includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Revised Commercial Development Plan), and 3) Attachment 2 (Royalty Payment
Information). 
 WHEREAS, the NIH and the Licensee desire that the Agreement be amended a first time as set forth below in order to
include co-owned intellectual property’ to the Licensed Patent Rights, modify’ the Licensed Field of Use, and modify’ the commercial development plan (Appendix E). 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the Licensee, intending to be bound, hereby
mutually agree to the following: 
  

	 	1)	 The Cover Page’s “Serial Number(s) of Licensed Patent(s) or Patent Application(s)” section and
Appendix A’s Patent(s) or Patent Application(s)’s section shall be deleted and replaced with the following: 

[***] 
  

	 	2)	 Appendix B shall be deleted in its entirety and replaced with the following: 

APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY 

[***] 
  

	 	3)	 Appendix E shall be deleted in its entirety and replaced with the revised commercial development plan in
Attachment 1. 

  

	 	4)	 Within sixty (60) days of the execution of this First Amendment, the Licensee shall pay the
NIH an amendment issue royalty in the sum of [***], and payment options may be found in Attachment 2. 

  

	 	5)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 2, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency’ and to give effect to the payment information in such Attachment 2. 

  

	 	6)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	 	7)	 The terms and conditions of this First Amendment shall, al the NIH’s sole option, be
considered by the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this First Amendment, and the First Amendment itself, to be null and void, unless this First Amendment is
executed by the Licensee and a fully’ executed original is received by’ the NIH within sixty (60) day’s from the date of tire NIH’s signature found al the Signature Page. 

 

	 	8)	 This First Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 1 of 16	  	

 FIRST AMENDMENT TO
L-164-2013/0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this First Amendment on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. 
 For the NIH: 
  

					
	
                          
                                         
             
 Richard U. Rodriguez
	  	
                          
  
 Date
	  	
	Director, Division of Technology Development and Transfer	  		  	
	Office of Technology Transfer	  		  	
	National Institutes of Health	  		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

Chief, Monitoring & Enforcement Branch, DTDT 
 Office of
Technology Transfer 
 National Institutes of Health 
 6011
Executive Boulevard, Suite 325 
 Rockville, Maryland 20852-3804 U.S.A. 

E-mail:    LicenseNotices_Reports@mail.nih.gov 

For the Licensee (Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the Licensee made
or referred to in this document are truthful and accurate.): 
  

					
	
                          
                                         
             
 Signature of Authorized Official
	  	
                          
  
 Date
	  	

 Elisabet de los Pinos President and Chief Executive Officer Aura Biosciences Inc. 

 

							
		 	I.	  	Official and Mailing Address for Agreement notices:	  	
				
		 		  	 Elisabet de los Pinos
	  	
		 		  	Name	  	
				
		 		  	 President and Chief Executive Officer
	  	
		 		  	Title	  	
				
		 		  	Mailing Address:	  	
				
		 		  	Aura Biosciences Inc.	  	
		 		  	85 Bolton Street	  	
		 		  	Cambridge, MA 02140	  	
				
		 		  	Email:                [***]	  	
		 		  	Phone:                [***]	  	

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 2 of 16	  	

							
		 		  	 With copy to:
	  	
				
		 		  	 Alison Lawton
	  	
		 		  	 Name
	  	
				
		 		  	 Chief Operating Officer
	  	
		 		  	 Title
	  	
				
		 		  	 Mailing Address:
	  	
				
		 		  	 Aura Biosciences Inc.
	  	
		 		  	 85 Bolton Street
	  	
		 		  	 Cambridge, MA 02140
	  	
				
		 		  	 Email:
                [***]
	  	
		 		  	 Phone:
                [***]
	  	
			
		 	 II.
	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):
				
		 		  	 Alison Lawton
	  	
		 		  	 Name
	  	
				
		 		  	 Chief Operating Officer
	  	
		 		  	 Title
	  	
				
		 		  	 Mailing Address:
	  	
				
		 		  	 Aura Biosciences Inc.
	  	
		 		  	 85 Bolton Street
	  	
		 		  	 Cambridge, MA 02140
	  	
				
		 		  	
Email:                [***]
	  	
		 		  	
Phone:                [***]
	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C.
§§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 3 of 16	  	

 ATTACHMENT 1 - REVISED COMMERCIAL DEVELOPMENT PLAN 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 4 of 16	  	

 ATTACHMENT 2 - ROYALTY PAYMENT OPTIONS 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 First Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 5 of 16	  	

 NATIONAL INSTITUTES OF HEALTH 

SECOND AMENDMENT TO
L-164-2013-0 

[***] 
  

	2)	 Appendix B shall be deleted in its entirety and replaced with the following: 

APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY 

[***] 
  

	3)	 Appendix E- Commercial Development Plan shall be appended with
Attachment 2. 

  

	4)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1, such provision(s)
is/are hereby’ amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 1. 

  

	5)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	6)	 The terms and conditions of this Second Amendment shall, at the NIH’s sole option, be
considered by the NTH to be withdrawn from the Licensee’s consideration and the terms and conditions of this Second Amendment, and the Second Amendment itself, to be null and void, unless this Second Amendment
is executed by the Licensee and a fully executed original is received by the NIH within sixty (60) days from the date of the NIH’s signature found at the Signature Page. 

 

	7)	 This Second Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 1 of 21	  	

 SECOND AMENDMENT TO L-164-2013-0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this Second Amendment on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. 
 For the NIH: 
  

							
	  
 Name: Richard Rodriguez,
M.B.A.
	 		  	  

Date                   
 
	  	
	Title: Associate Director	 		  		  	
	Office: Technology Transfer Center, National Cancer Institute	 		  		  	
	National Institutes of Health	 		  		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration Monitoring & Enforcement Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard,
Suite 325 Rockville, Maryland 20852-3804 U.S.A. 

E-mail:    LicenseNotices_Reports@mail.nih.gov 

For the Licensee Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the Licensee made or
referred to in this document are truthful and accurate.): 
  

							
	  
 Signature of Authorized
Official
	 		  	  

Date                    
	  	
	Name: Elisabet de los Pinos	 		  		  	
	Title: President and Chief Executive Officer	 		  		  	

  

					
	I.    	  	Official and Mailing Address for Agreement notices:	  	
			
		  	 Elisabet de los Pinos
	  	
		  	Name	  	
			
		  	 President and Chief Executive Officer
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 Aura Biosciences Inc.
	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge, MA 02140
	  	
			
		  	  
	  	

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 2 of 21	  	

					
	    	  	Email Address:	  	[***]        
			
		  	Phone:	  	[***]        

					
			
		  	Fax:            	  	                                     
                                   

					
			
		  	With copy to:	  	
			
		  	 Michele Keough
	  	
			
		  	Name	  	
			
		  	 Senior Vice President
	  	
			
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 Aura Biosciences Inc
	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge. MA 02140
	  	

					
			
		  	Email Address:	  	[***]
			
		  	Phone:	  	[***]
		
	 II.
	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):

  

			
	 Kylie Reynolds
	 	
	Name	 	
		
	VP. Finance	 	
	Title	 	
		
	Mailing Address:	 	
		
	 Aura Bioscience, Inc.
  

85 Bolton Street
	 	
		
	 Cambridge. MA 02140
	 	
		
	  
	 	

  

			
	Email Address:	  	[***]                                     
                                         
                  
		
	Phone:	  	[***]                                     
                                         
                  
		
	Fax:	  	                                    
                                         
                            

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 3 of 21	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. $$3801-3812 (civil liability) and
18 U.S.C. $1001 (criminal liability including fine(s) or imprisonment). 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 4 of 21	  	

 ATTACHMENT 1 - ROYALTY PAYMENT OPTIONS 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 5 of 21	  	

 ATTACHMENT 2 - APPENDIX E ADDENDUM 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 6 of 21	  	

 NATIONAL INSTITUTES OF HEALTH 

THIRD AMENDMENT TO
L-164-2013-0 

Tax ID No: [***] 
 This is the third
amendment (‘Third Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Aura Biosciences, Inc. having
an effective date of September 3, 2013 and having NIH Reference Number L-164-2013-0, its First Amendment
having an effective date of September 28, 2015 and having NIH Reference Number L-164-2013-1, and its Second
Amendment, having an effective date of August 20, 2018 and having NTH Reference Number
L-164-2013-2 (collectively, “Agreement”). This Third Amendment, having NIH Reference Number L-164-2013-3, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive
Boulevard, Suite 325, Rockville, Maryland 20852- 3804, U.S.A., and Aura Biosciences, Inc., having an office at 85 Bolton Street, Cambridge MA 02140 (the “Licensee”). This Third Amendment includes, in addition to the
amendments made below, 1) a Signature Page, 2) Attachment 1 (Appendix E- Commercial Development Plan Addition), and Attachment 2 (Royalty Payment Information). 

WHEREAS, the NIH and the Licensee desire that the Agreement be amended a third time as set forth below in order to address combination
products in the Agreement, transfer control of the patent prosecution of the Licensed Patent Rights, update the Benchmarks in Appendix D, and update the Commercial Development Plan in Appendix E. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the Licensee, intending to be bound, hereby
mutually agree to the following: 
  

	1)	 Article 7 shall be deleted in its entirety and replaced with the following: 

 

	 	7.	 PATENT FILING. PROSECUTION. AND MAINTENANCE 

 

	 	7.1	 [***] 

  

	 	7.2	 [***] 

  

	 	7.3	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent Rights,
which comments and suggestions shall be considered by the other party. 

  

	2)	 Article 11 shall be deleted in its entirety and replaced with the following: 

 

	 	11.	 INFRINGEMENT AND PATENT ENFORCEMENT. 

 

	 	11.1	 The NIH and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

 

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for. infringement of presumably valid
claims in the Licensed Patent Rights; 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 1 of 17	  	

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights; and 

 

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify the
NIH in writing. If the NIH does not notify the Licensee of its intent to pursue legal action within ninety (90) days, the Licensee shall be free to initiate suit. The NIH shall have a continuing right to
intervene in the suit. The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee may request the Government to initiate or join in any suit
if necessary, to avoid dismissal of the suit. Should the Government be made a party to any suit, the Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the
motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and progress of any litigation.
Before the Licensee commences an infringement action, the Licensee shall notify the NIH and give careful consideration to the views of the NIH and to any potential effects of the litigation on the public health in
deciding whether to bring suit. 

  

	 	11.3	 In the event that a declaratory judgment action alleging invalidity or noninfringement of any of the
Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the Licensee under Paragraph 11.2, pursuant to this Agreement and the
provisions of 35 U.S.C. Part 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights,-provided,
however, that the NIH shall have a continuing right to intervene in the suit; and 

  

	 	(d)	 respond to the legal action within ninety (90) days. The Licensee shall take no action to compel
the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the Government to initiate or to join any suit if necessary, to avoid dismissal of the suit. Should the Government
be made a party to any suit by motion or any other action of the Licensee, the Licensee shall reimburse the Government for any costs, expenses, or fees, which the Government incurs as a result of the motion or other
action. If the Licensee elects not to defend against the declaratory judgment action, the NIH, at its option, may do so at its own expense. In all cases, the Licensee agrees to keep the NIH reasonably apprised of the status and
progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the NIH and give careful consideration to the views of the NIH and to any potential effects of the litigation on the
public health in deciding whether to bring suit. 

  

	 	11.4	 In any action under Paragraphs 11.2 or 11.3, the expenses, including costs, fees, attorney fees, and
disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee, which exceeds the expenses incurred with prosecuting or defending any action therein, through court judgment or settlement, shall be treated
as Net Sales and subject to earned royalties. The Licensee shall provide an accounting of any expenses that are deducted from Net Sales under this Paragraph 11.4. 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 2 of 17	  	

	 	11.5	 The NIH shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The NIH agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	3)	 Paragraph 14.7 shall be deleted in its entirety and replaced with the following: 

 

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) without the prior written consent of the NIH. The parties agree that the identity of the parties is material to the
formation of this Agreement and that the obligations under this Agreement are nondelegable. [***] 

  

	4)	 Appendix C - Royalties, Paragraph III, shall be deleted in its entirety and replaced with the following:

 The Licensee agrees to pay the NIH earned royalties of [***]. 

 

	5)	 Appendix D - Benchmarks and Performance, shall be deleted in its entirety and replaced with the following:

 The Licensee agrees to the following Benchmarks for its performance under this Agreement and,
within thirty (30) days of achieving a Benchmark, shall notify the NIH that the Benchmark has been achieved. 

[***] 
  

	6)	 Appendix E - Commercial Development Plan shall be appended with Attachment I. 

 

	7)	 [***] 

  

	8)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 2, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 2. 

  

	9)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	10)	 The terms and conditions of this Third Amendment shall, at the NIH’s sole option, be
considered by the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this Third Amendment, and the Third Amendment itself, to be null and void, unless this Third Amendment is
executed by the Licensee and a fully executed original is received by the NIH within [***] days from the date of the NIH’s signature found at the Signature Page. 

 

	11)	 This Third Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 3 of 17	  	

 THIRD AMENDMENT TO L-164-2013-0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this Third Amendment on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. 
 For the NIH: 
  

					
	Name: Richard U. Rodriguez	 	 	  	 Date

	Title: Associate Director	 		  	
	Office: National Cancer Institute	 		  	
	National Institutes of Health	 		  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: [***] 
 For the Licensee (Upon information and belief, the undersigned expressly certifies or affirms that
the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

					
	Signature of Authorized Official	 	 	  	Date

 Name: Elisabet de los Pinos Title: President and CEO 

 

					
	 I.    
	  	 Official and Mailing Address for Agreement notices:
	  	
			
		  	 Elisabet de los Pinos
	  	
		  	Name	  	
			
		  	 President and CEO
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge. MA 02140
	  	
			
		  	  
	  	

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 4 of 17	  	

					
		  	Email Address:	  	[***]                                     
          
			
		  	Phone:	  	[***]                                     
          
			
	    	  	Fax:	  	                                     
                   

					
		
	II.	  	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):
			
		  	 Elisabet de los Pinos
	  	
		  	Name	  	
			
		  	 President and CEO
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
			
		  	 85 Bolton Street
	  	
			
		  	 Cambridge. MA 02140
	  	
			
		  	  
	  	
			
		  	  
	  	

  

					
		  	Email Address:	  	[***]                                     
          
			
		  	Phone:	  	[***]                                     
          
			
	    	  	Fax:	  	                                     
                   

Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and
during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C., $$3801-3812 (civil liability) and 18 U.S.C. $1001 (criminal liability including
fine(s) or imprisonment). 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 5 of 17	  	

 ATTACHMENT 1 - ADDITION TO APPENDIX E -COMMERCIAL DEVELOPMENT PLAN 

[***] 

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 6 of 17	  	

 ATTACHMENT 2 - ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 
 [***]

  

					
	 CONFIDENTIAL – NIH
	  		  	
	 Second Amendment of L-164-2013/0
	  	FINAL Aura Biosciences	  	9-16-15
	 Model 09-2006 (updated 8-20120
	  	Page 7 of 17EX-10.9

 Exhibit 10.9 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 
  

 
  

EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

Dated January 31, 2014 

Between 
 LI-COR, Inc. 
 And 

Aura Biosciences, Inc. 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 ARTICLE 1
	 	DEFINITIONS	  	 	1	 
	 ARTICLE 2
	 	LICENSE	  	 	5	 
	 2.1
	 	Grant	  	 	5	 
	 2.2
	 	Sublicenses	  	 	5	 
	 2.3
	 	Consideration for Expanded Field	  	 	5	 
	 2.4
	 	No Implied Rights or Licenses	  	 	5	 
	 ARTICLE 3
	 	FEES, ROYALTIES, AND PAYMENTS	  	 	6	 
	 3.1
	 	License Issue Fee	  	 	6	 
	 3.2
	 	Royalty	  	 	6	 
	 3.3
	 	Milestone Payments	  	 	7	 
	 3.4
	 	Method of Payment	  	 	7	 
	 3.5
	 	Late Payments	  	 	8	 
	 3.6
	 	Taxes	  	 	8	 
	 ARTICLE 4
	 	REPORTS, RECORDS, AND INSPECTIONS	  	 	8	 
	 4.1
	 	Reports	  	 	8	 
	 4.2
	 	Records and Inspections	  	 	8	 
	 ARTICLE 5
	 	ADDITIONAL OBLIGATIONS OF THE PARTIES	  	 	9	 
	 5.1
	 	Due Diligence	  	 	9	 
	 5.2
	 	Compliance with Law	  	 	10	 
	 5.3
	 	Data Sharing	  	 	10	 
	 5.4
	 	Prosecution, Maintenance, and Enforcement	  	 	10	 
	 5.5
	 	Challenges	  	 	10	 
	 5.6
	 	Promotional Materials and Product Labeling	  	 	11	 
	 5.7
	 	Publicity and Use of Marks	  	 	11	 
	 5.8
	 	Improvements	  	 	11	 
	 ARTICLE 6
	 	SUPPLY OFIR DYE 700DX	  	 	11	 
	 6.1
	 	Supply & Exclusivity	  	 	11	 
	 6.2
	 	Forecasting	  	 	11	 
	 6.3
	 	Orders and Acceptance	  	 	12	 
	 6.4
	 	Pricing and Payment	  	 	12	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
			
	 6.5
	 	Delivery	  	 	12	 
	 6.6
	 	Inspection and Rejection	  	 	12	 
	 6.7
	 	Safety Stock	  	 	13	 
	 6.8
	 	Secondary Supplier	  	 	13	 
	 ARTICLE 7 
	 	REPRESENTATIONS AND WARRANTIES	  	 	13	 
	 7.1
	 	Of Both Parties	  	 	13	 
	 7.2
	 	Of LI-COR	  	 	14	 
	 7.3
	 	Disclaimer	  	 	15	 
	 ARTICLE 8 
	 	CONFIDENTIALITY	  	 	15	 
	 8.1
	 	Confidentiality	  	 	15	 
	 8.2
	 	Exceptions	  	 	15	 
	 8.3
	 	Unauthorized Disclosure	  	 	16	 
	 8.4
	 	Notification	  	 	16	 
	 8.5
	 	Duration	  	 	16	 
	 ARTICLE 9 
	 	TERM AND TERMINATION	  	 	16	 
	 9.1
	 	Term	  	 	16	 
	 9.2
	 	Termination	  	 	16	 
	 9.3
	 	Effect of Termination	  	 	17	 
	 ARTICLE 10
	 	INDEMNIFICATION	  	 	18	 
	 10.1
	 	Indemnification	  	 	18	 
	 10.2
	 	Notice and Defense of Third-Party Claims	  	 	18	 
	 ARTICLE 11
	 	INSURANCE 	  	 	19	 
	 11.1
	 	Requirements	  	 	19	 
	 11.2
	 	Other Obligations	  	 	19	 
	 11.3
	 	Third-Party Requirements	  	 	19	 
	 ARTICLE 12
	 	LIMITATION OF LIABILITY	  	 	19	 
	 ARTICLE 13
	 	MISCELLANEOUS	  	 	19	 
	 13.1
	 	Force Majeure	  	 	19	 
	 13.2
	 	Governing Law and Forum	  	 	20	 
	 13.3
	 	Assignment	  	 	20	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
			
	 13.4
	 	Merger	  	 	20	 
	 13.5
	 	Notices	  	 	20	 
	 13.6
	 	General Interpretive Provisions	  	 	21	 
	 13.7
	 	Severability	  	 	21	 
	 13.8
	 	Amendments	  	 	21	 
	 13.9
	 	Waivers	  	 	21	 
	 13.10
	 	Counterparts	  	 	21	 
	 13.11
	 	Independent Contractors	  	 	21	 
	 13.12
	 	Third-Party Beneficiaries	  	 	21	 
	 13.13
	 	Construction	  	 	21	 
	 13.14
	 	Export Controls	  	 	22	 
	 13.15
	 	US Dollars	  	 	22	 
	 13.16
	 	Further Assurances	  	 	22	 
	 13.17
	 	Dispute Resolution	  	 	22	 

  

  
 -iii- 

 EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

This Exclusive License and Supply Agreement (this “Agreement”) is dated January 31, 2014 (“Effective
Date”) and is between LI-COR, Inc., a Nebraska corporation with a principal address of 4647 Superior Street, Lincoln, Nebraska 68504
(“LI-COR”), and Aura Biosciences, Inc., a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (“Aura”). LI-COR and Aura individually referred to herein as a “Party” and collectively as the “Parties”. 

WHEREAS, LI-COR has developed a certain proprietary dye, IRDye 700DX, for use in targeted
imaging agents, as well as certain technology concerning the binding of such dye to an optical agent; 
 WHEREAS, Aura desires to license-in, and LI-COR is willing to grant such license to, such dye and technology, on an exclusive basis, for commercial use in the limited field of the treatment and
diagnosis of ocular cancers in humans using Aura’s nanoparticles conjugated to such dye; and 
 WHEREAS, in connection with such
license grant to Aura, Aura desires to have LI-COR supply its requirements of such IR Dye 700DX, and LI-COR is willing to supply such IR Dye 700DX, to Aura. 

NOW THEREFORE, in mutual consideration of the covenants and obligations set forth in this Agreement, the receipt and legal sufficiency
of which is hereby acknowledged, accepted and agreed to, the Parties, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1

 Definitions 

For purposes of this Agreement, the following capitalized terms, whether used in the singular or plural, have the respective meanings set
forth below: 
 1.1    “Affiliate” means, with respect to any given Person, any other Person at
the time directly or indirectly controlling, controlled by or under common control with that Person. “Control” means the possession of, directly or indirectly, of the power to direct or cause the direction of the management and policies of
a Person, whether through ownership of voting securities, by contract, or otherwise. 
 1.2    “Commercially
Reasonable Efforts” means [***]. 
 1.3    “Confidential Information” means any
and all confidential or proprietary information and materials of or concerning a Party or the Licensed Patent or Know-How, including, but not limited to, commercial, financial, and technical information,
substances, formulations, techniques, methodologies, customer or client lists, programs, procedures, data, documents, know-how, protocols, results of experimentation and testing, specifications, databases,
business plans, trade secrets, business arrangements, information regarding specific transactions, long-term plans and goals, and the terms and conditions of this Agreement. The Licensed Patent and Know-How
will be treated as the Confidential Information of LI-COR. 

 1.4    “EU” means the European Union. 

1.5    “FDA” means the United States Food and Drug Administration, including all agencies under
its control, and any successor agency thereto. 
 1.6    “First Commercial Sale” means the first
sale of a Licensed Product by Aura, an Affiliate or a Sublicensee to a Third Party, following Regulatory Approval of such Licensed Product. 

1.7    “Generic Product” means, with respect to a Licensed Product, a product that
(a) obtained Regulatory Approval solely by means an ANDA procedure (or any foreign equivalent thereto) under Section 505 (j) of the Federal Food, Drug, and Cosmetic Act, in the United States for establishing equivalence to such Licensed
Product, with the Licensed Product as the reference listed drug, (b) is AB rated and legally substituted by pharmacies for such Licensed Product and (c) is legally marketed by an entity other than the Parties. 

1.8    “Improvements” means any changes, discoveries, improvements, developments, enhancements, or
modifications in the Know-How or IRDye 700DX however arising and occurring at any time during the Term. 

1.9    “Infringement” means any infringement as determined by applicable Law, including direct
infringement, contributory infringement, and any inducement to infringe. 
 1.10    “IRDye 700DX”
means LI-COR’s IRDye 700DX Carboxylate. 
 1.11    “Know-How” means any and all unpatented technical information, research data, designs, trade secrets, confidential information, methods, techniques, results, formulas, process information, clinical
data, or other information that: (a) is known to or acquired by LI-COR during the Term; (b) LI-COR has the right to license; (c) is outside the public
domain; and (d) is related to LI-COR’s (i) IR Dye 700DX, including but not limited to, chemical synthesis and conjugation methods or (ii) the formulation of IR Dye 700DX. 

1.12    “Law” means any federal, state, local, municipal, foreign, international, multinational,
or other administrative order, constitute, law, ordinance, principle of common law, regulation, statute, or treaty. 

1.13    “Licensed Field” means use in the treatment and diagnosis of ocular cancers in humans.

 1.14    “Licensed Patent” means the U.S. Patent No. 7,005,518, entitled,
“Phthalocyanine Dyes”, which was issued on February 28, 2006 and filed on October 23, 2003, along with the inventions described and claimed therein. 

1.15    “Licensed Product” means nanoparticles conjugated with IR Dye 700DX. 

1.16    “Losses” means any and all losses, damages, liabilities judgments, costs, and expenses (including
reasonable attorneys’ fees) based on, arising out of, or incidental to any and all claims, actions, demands, suits, causes of action, brought or asserted against a Party by a Third Party. 

  
 2 

 1.17    “MAA” means any marketing authorization
application for a country or region in the Territory, requesting approval from the applicable Regulatory Authority for commercial sale (including the marketing, promotion and distribution) of a Licensed Product in such country or region in the
Territory, and any equivalent application submitted in any such country in the Territory, including all additions, deletions or supplements thereto, and as any and all such requirements may be amended, or supplanted, at any time. 

1.18    “Minimum Royalty” means [***]. 

1.19    “NDA” means a New Drug Application as defined in Title 21 of the U.S. Code of Federal
Regulations, §314.80 et seq., in accordance with the requirements of the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the regulations promulgated thereunder, and all amendments and supplements thereto, filed with the FDA,
including all documents, data, and other information that are necessary for gaining Regulatory Approval in the Territory, and all additions, supplements, extension and amendments thereto. 

1.20    “Net Sales” means the gross sales revenues and fees billed or received by Aura, its
Affiliates and Sublicensees for sales of a Licensed Product to independent or unaffiliated Third Party purchasers of such Licensed Product, less deductions with respect to such gross amounts to the extent that such deductions are either included in
the billing as a line item as part of the gross amount invoiced, or otherwise specifically documented in accordance with generally acceptable accounting principles to be specifically attributable to actual sales of such Licensed Product: 

[***] 
 In the case of discounts on packages of
products or services which include Licensed Product in those countries in which such is legally permissible (“Packages”), the discount applied to Licensed Product within the Package shall be no greater than the smallest
discount of a product in the Package determined based on the list price of all such products. If a Licensed Product or another product in the Package does not have a list price, then the Parties will agree on the “Fair Value” of such
product in place of the list place for the purpose of calculating royalties hereunder. For clarity, a “sale” of a Licensed Product is deemed to occur upon the invoicing, or if no invoice is issued, upon the earlier of shipment or transfer
of title in the Licensed Product. 
 1.21    “Person” means any individual, corporation
(including any nonprofit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, governmental authority, or other entity. 

1.22    “Phase III Clinical Trial” means an expanded human clinical trial intended to gather
information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship and to provide an adequate basis for physician labeling. 

1.23    “Regulatory Approval” means any and all approvals (including any applicable governmental price
and reimbursement approvals), licenses, registrations or authorizations from 

  
 3 

 
any Regulatory Authority necessary for the use, storage, import, export, distribution, transport, promotion, marketing, commercialization and regular and continuance commercial sale (including
packaging and labeling) of the Licensed Product, NDA filings (or any foreign equivalents thereof) for the Licensed Product, and product license applications of the Licensed Product. 

1.24    “Regulatory Authority” means any federal, national, multinational, regional, state,
provincial or local regulatory agency, department, bureau, commission, council or other governmental entity with authority to grant a Regulatory Approval or having jurisdiction over the manufacture, development or commercialization of the Licensed
Product. 
 1.25    “Territory” means the entire world. 

1.26    “Third Party” means any party other than the Parties or either Party’s Affiliates.

 1.27    “Third Party Royalties” means any royalties Aura owes to one or more Third Parties
pursuant to one or more licenses to intellectual property rights entered into by Aura to avoid Infringement of such rights that are reasonably necessary for the practice of the Licensed Patent in the manufacture, use, or sale of the IR Dye 700DX, or
to avoid infringement-related litigation with respect to the practice of the Licensed Patent. 

1.28    “Unit” means a single unit of Licensed Product packaged for use in a single setting. 

1.29    “Valid Claim” means an issued and unexpired claim of the Licensed Patent, that has not
been held unpatentable, invalid, or unenforceable by a final unappealable decision of a court or other government agency of competent jurisdiction, in an unappealed or unappealable decision, admitted to be invalid or unenforceable through reissue, re-examination, disclaimer, or otherwise. 
 1.30    Other Definitions. The
following definitions have the meanings ascribed to them in the corresponding Section: 
  

			
	 Definition
	  	Section
	 A.A.A.
	  	13.17(b)
	 Achievement Date
	  	5.1
	 Agreement
	  	Introduction
	 Aura
	  	Introduction
	 Diligence Event
	  	5.1
	 Dispute
	  	13.17
	 Effective Date
	  	Introduction
	 Executives
	  	13.17(a)
	 Expanded Field
	  	2.3
	 Forecast
	  	6.2
	 License
	  	2.1
	 LI-COR
	  	Introduction
	 Milestone
	  	3.3

  
 4 

			
	 Milestone Payment
	  	3.3
	 Package
	  	1.20
	 Party(ies)
	  	Introduction
	 Royalty
	  	3.2
	 Specifications
	  	6.1
	 Sublicensee
	  	2.2
	 Supply Failure
	  	6.8
	 Term
	  	9.1

 ARTICLE 2 

License 

2.1    Grant. Subject to the terms and conditions of this Agreement, LI-COR
hereby grants to Aura an exclusive, royalty-bearing, license (“License”) under the Licensed Patent, Improvements and Know-How to research, develop, make, have made, use, have used,
market, sell, have sold, distribute, have distributed, export and have imported Licensed Product for the Licensed Field in the Territory during the Term. Notwithstanding the foregoing, such License does not include the right to make or have made IR
Dye 700DX. 
 2.2    Sublicenses. Subject to the terms and conditions of this Agreement, Aura shall have the
right to grant sublicenses under the License to (a) to its Affiliates and (b) to Third Parties (“Sublicensee”), to make, have made, market, sell and have sold Licensed Product in the Licensed Field in the
Territory. Aura shall remain responsible for complying with all terms and conditions of this Agreement regardless of any grant to a Sublicensee or Affiliate. In addition, Aura shall require that each of its Affiliates and Sublicensees accept all of
the relevant terms and conditions of this Agreement as if such Affiliates or Sublicensees were a party to this Agreement, and shall provide LI-COR with a copy of each agreement with a Sublicensee upon execution of such agreement. For clarity, Aura
shall have no right to grant a sublicense to its Affiliates or any Third Party under the Licensed Patent and Know-How to make or have made IRDye 700DX in the Licensed Field in the Territory. Upon termination
or expiration of this Agreement for any reason, any Sublicensee not then in default under its agreement with Aura or an Affiliate shall have the right to seek a license directly from LI-COR. LI-COR agrees to negotiate such license in good faith under reasonable terms and conditions consistent with this Agreement; provided, however, whether LI-COR enters into any
such license shall be at the sole discretion of LI-COR. 

2.3    Consideration for Expanded Field. At any time during the Term,
LI-COR hereby agrees to consider any request by Aura to negotiate a non-exclusive, royalty-bearing license under the Licensed Patent, Improvements and Know-How to research, develop, make, have made, use, have used, market, offer for sale, sell, have sold, distribute, have distributed, export and import products for the diagnosis and treatment of cancers in
indications other than ocular cancers (the “Expanded Field”) in the Territory; provided, that LI-COR is not obligated to negotiate or grant any such license. It is understood generally
that the aggregate financial terms of a non-exclusive license in the Expanded Field is likely to be less than financial terms of an exclusive license of an identical scope.  

2.4    No Implied Rights or Licenses. Neither Party grants to the other Party any rights or licenses in or to any
patent, know-how or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement. 

  
 5 

 ARTICLE 3 

Fees, Royalties, and Payments 

3.1    License Issue Fee. In partial consideration for the license and rights granted to Aura under this Agreement,
Aura shall pay LI-COR the following non-refundable, non-creditable license issue fee of $[***] according to the following
schedule: 
  

					
	 Issue Fee Portion
	  	Date Due	 
	 $[***]
	  	 	[	***] 
	 $[***]
	  	 	[	***] 
	 $[***]
	  	 	[	***] 
	 Total:
	  	$	[	***] 

 3.2    Royalty. In partial consideration for the license and rights granted to Aura
under this Agreement, Aura shall, on a country-by-country basis, during the Term pay LI-COR the following royalty
(“Royalty”) on Net Sales. The Royalties due shall be calculated on an incremental basis and paid annually. [***]. 
  

					
	 Annual Net Sales
	  	Royalty	 
	 [***]
	  	 	[	***]% 
	 [***]
	  	 	[	***]% 
	 [***]
	  	 	[	***]% 
	 [***]
	  	 	[	***]% 

 (a)    If the Royalty due for any calendar quarter is less than the Minimum Royalty
applicable for such calendar quarter and the total amount of Royalty paid for each of the calendar quarters in the same calendar year as such calendar quarter is less than the total Minimum Royalty due in the aggregate for such calendar quarters,
Aura shall pay LI-COR the Royalty plus the difference between the Minimum Royalty and the Royalty for such calendar quarter, to be trued up at the end of each calendar year. 

(b)    All such payments must be made quarterly, in accordance with Section 4.1 (b) and this
Article 3. In order to ensure LI-COR the full royalty payments contemplated hereunder, Aura agrees that in the event any Licensed Product is sold to an Affiliate or a Sublicensee or to a
corporation, firm, or association with which Aura has any agreement, understanding, or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving
division of profits or special rebates or allowances), the royalties to be paid hereunder for such Licensed Product will be based upon the greater of (x) the net selling price (per Net Sales) at which the purchaser of the Licensed Product
resells such product to the end user; (y) the fair market value of the Licensed Product; or (z) the net selling price (per Net Sales) of Licensed Product paid by the purchaser. 

  
 6 

 (c)    In the event that, on a country-by-country basis, the Licensed Product is not covered by a Valid Claim in a country and there is a Generic Product in such country, then the Royalty on Net Sales of Licensed Product in such country
due to LI-COR shall be reduced by [***]% for the remainder of the Term. 

(d)    In the event that Aura receives a communication from a Third Party alleging infringement of or notification of such
Third Party’s patent rights as they relate to the research, development, manufacture, or use of IRDye 700DX, Aura shall notify LI-COR of such communication, and Aura shall take into consideration LI-COR’s comments regarding such communication. In the event that Aura is required to pay Third Party Royalties in order to license rights to the IRDye 700DX, then Aura may deduct [***]of the Third Party
Royalties paid by Aura in such calendar quarter from the Royalty due to LI-COR for such calendar quarter, provided that in no event shall the Royalty due to LI- COR be
reduced by more than [***]. 
 3.3    Milestone Payments. In partial consideration for the license and rights
granted to Aura under this Agreement, Aura shall pay to LI-COR each of the following milestone payments (“Milestone Payments”) within [***] after the occurrence of the applicable
milestone (“Milestone”) only for the first achievement of the Milestone event below for each Licensed Product, whether such event results from the activities of Aura or its Affiliates. 

 

					
	 Milestone
	  	Milestone Payment	 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 Total:
	  	$	[	***] 

 All Milestone Payments are non-refundable and
non-creditable against any other royalties, fees, or payments hereunder. For clarity, Milestone Payments are owed on a Licensed Product by Licensed Product basis. Notwithstanding the foregoing, with respect to
the development of more than one candidate constituting a Licensed Product, if any milestone payments have been made with respect to a candidate the development of which is abandoned by Aura and Aura pursues the development of a subsequent candidate
constituting part of such Licensed Product, all milestone payments previously made with respect to such abandoned candidate shall be credited towards the milestones that would otherwise be due and payable with respect to one or more subsequent
candidates. 
 3.4    Method of Payment. All payments to LI-COR hereunder
shall be made by deposit of United States Dollars in the requisite amount to such bank account as LI-COR may from time to time designate by written notice to Aura. With respect to sales not denominated in
United States Dollars, Aura shall convert applicable sales in foreign currency into United States Dollars based on the average of the conversion rate reported in The Wall Street Journal on the last working day of each month in the calendar quarter
of the applicable calendar quarter. Based 

  
 7 

 
on the resulting sales in USD, the then applicable royalties shall be calculated. The Parties may vary the method of payment set forth herein at any time upon mutual written agreement, and any
change shall be consistent with the local Law at the place of payment or remittance. 
 3.5    Late Payments. In
the event that any payment (other than a payment disputed in good faith) hereunder is not made when due, the amount due will accrue interest calculated at the annual rate of the sum of (a) four percent (4%) plus (b) the
prime interest rate quoted by The Wall Street Journal on the date said payment is due, the interest being compounded on the last day of each calendar quarter; provided that in no event will said annual interest rate exceed the maximum
interest rate allowed by law. Each such payment when made must be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof will not negate or waive the right of LI-COR to
seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment, including termination of this Agreement as set forth in Section 9.2. 

3.6    Taxes. All fees, royalties, and other payments are exclusive of any national, state, and local sales, use,
value added, and other taxes, customs duties, or similar tariffs and fees which Aura may be required to collect or pay. Should any tax or levy be made, Aura agrees to pay such tax or levy and indemnify LI-COR
against any claim for such tax or levy demanded. Aura shall pay any withholding taxes required by applicable Law. 
 ARTICLE 4 

Reports, Records, and Inspections 

4.1    Reports. 

(a)    Summary Reports. Not less than once every six (6) months, Aura shall provide LI-COR with a summary report, which must describe a summary-level review and/or update of the research, development, and commercialization activities undertaken by Aura and its Affiliates and Sublicensees with
respect to Licensed Product during the period covered by the report and/or update since the last report. Each such report shall include a summary of work completed, a summary of work in progress, a current schedule of anticipated regulatory
approvals, sublicensing efforts, if any, and market plans for introduction of Licensed Product. 
 (b)    Royalty
Reports. Aura shall provide LI-COR with quarterly royalty reports, due within [***] after the end of each calendar quarter. Each such royalty report shall disclose the number of Units of Licensed Product
sold, the total Net Sales of such Licensed Product, and the resulting royalties due to LI-COR as a result of either number of Units or Net Sales by Aura and its Affiliates and Sublicensees. Payment of any such
royalties due will accompany such royalty report. If no amounts are due LI-COR for any calendar quarter, the report shall so state. 

4.2    Records and Inspections. Aura shall make and retain, for a period of three (3) years following
the period of each report required by Section 4.1, true and accurate records, files, and books of account containing all the data reasonably required for the full computation and verification of sales and other information required in
Section 4.1. Such books and records will be in accordance with generally accepted accounting principles consistently applied. Subject to 

  
 8 

 
the terms of the Confidentiality Agreement by and between the Parties, Aura will permit the inspection and copying of such records, files, and books of account by
LI-COR or its agents during regular business hours upon [***] prior written notice to Aura. Aura may require that the inspection be performed by an independent certified public accountant (CPA) subject to a
confidentiality agreement reasonably acceptable to Aura. Inspections may not be made more than once each calendar year. All costs of each such inspection and copying will be paid by LI-COR; provided that if
any such inspection reveals that an error has been made in Aura’s favor in an amount equal to five percent (5%) or more of the amounts actually owed, all costs will be borne by Aura. Aura agrees to include in any agreement with its
Sublicensees which permits any such party to research, develop, use, offer for sale, sell, or have sold Licensed Product, a provision requiring such party to retain records of sales of Licensed Product and other information as required in
Section 4.1 and permit LI-COR or its agents to inspect such records as required by this Section 4.2. 

ARTICLE 5 
 Additional
Obligations of the Parties 
 5.1    Due Diligence. 

(a)    General. Aura shall use Commercially Reasonable Efforts to develop and commercialize Licensed Product, and
thereafter it shall use Commercially Reasonable Efforts to keep Licensed Product readily available to the public. 

(b)    Key Diligence Obligations. Aura shall use Commercially Reasonable Efforts to achieve each of the following
diligence events (each, a “Diligence Event”) by the corresponding achievement date set forth below (“Achievement Date”). Notwithstanding the foregoing, Aura shall have the right and option to extend any
Achievement Date for a Diligence Event by six (6) month increments, but not more than three (3) times per Diligence Event, by making a [***] payment to LI-COR prior to the expiration of the
Achievement Date for such Diligence Event. 
  

					
	 Diligence Event
	  	Achievement Date	 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

 In the event that Aura fails to achieve any Diligence Event by the applicable Achievement Date, and Aura does
not elect to extend the applicable Achievement Date as permitted by this Section 5.1(b), then this License shall automatically convert to a non-exclusive license. 

  
 9 

 5.2    Compliance with Law. In all activities undertaken pursuant
to this Agreement, each Party covenants and agrees that it will comply in all material respects with applicable Law. 

5.3    Data Sharing. 

(a)    By Aura. Aura will provide LI-COR with a right to reference
Aura’s “Drug Master File,” or DMF, relating to each Licensed Product and with reasonable access to all data and other information resulting from Aura’s research and development activities regarding IR Dye 700DX. Further, to the
extent required by LI-COR with respect to its regulatory filings or manufacturing processes, Aura will provide LI-COR reasonable access to the required raw or summary
data within the applicable DMF of Aura, subject to the confidentiality obligations herein and any applicable confidentiality obligations Aura may have to Third Parties. The Parties will cooperate in good faith in furtherance of the foregoing. 

(b)    By LI-COR. LI-COR will
provide Aura with a right to reference LI-COR’s DMF for IR Dye 700DX. Further, to the extent required by Aura with respect to its regulatory filings or manufacturing processes, LI-COR will provide Aura reasonable access to the required raw or summary data within such DMF of LI-COR, subject to the confidentiality obligations herein and any applicable
confidentiality obligations LI-COR may have to Third Parties. LI-COR will reasonably assist Aura, upon its written request, with the CMC section of regulatory filings.
The Parties will cooperate in good faith in furtherance of the foregoing. 
 5.4    Prosecution, Maintenance, and
Enforcement. 
 (a)    Prosecution and Maintenance. LI-COR will have
the sole right, in its sole discretion, to prepare, file, prosecute, and maintain the Licensed Patent and any patents or patent applications concerning any Improvements. Aura shall promptly inform LI-COR as to
all matters that come to its attention that may affect the preparation, filing, prosecution or maintenance of the Licensed Patent. 

(b)    Enforcement. LI-COR and Aura shall notify each other promptly of
each infringement or possible infringement of the Licensed Patent, as well as any facts that may affect the validity, scope, or enforceability of the Licensed Patent, of which either Party becomes aware. Aura shall cooperate fully with LI-COR in connection with any action or defense relating to infringement, invalidity, or unenforceability. Aura shall promptly provide LI-COR with access to all necessary
documents, and agrees to render reasonable assistance in response to a request by LI-COR. Aura agrees not to take any action or compel LI-COR either to initiate actions
for infringement or defend against allegations of invalidity or unenforceability of the Licensed Patent. 

5.5    Challenges. If Aura or any of its Affiliates (a) brings any action for a declaratory judgment of the
invalidity, unenforceability, or non-infringement of any of the Licensed Patent, (b) initiates a re-examination proceeding with respect to any Licensed
Patent, or (c) asserts any other legal challenge to the ownership, infringement, validity or enforceability of any of the Licensed Patent or Know-How, then in any case LI-COR may terminate this Agreement without notice. Aura shall reimburse LI-COR for all costs and expenses it may have incidental to such a termination. 

  
 10 

 5.6    Promotional Materials and Product Labeling. Subject to
Section 5.7(b), Aura agrees that in all advertising, marketing, publicity, promotional, sales, product literature, and similar materials for public distribution or use concerning any Licensed Product, as well on all packaging for all Licensed
Product, Aura shall prominently identify such Licensed Product as using LI-COR’s IRDye 700DX “under license from LI-COR, Inc.” Aura further agrees that
all packaging for all Licensed Product will be marked with the number of the Licensed Patent in accordance with each country’s patent laws. 

5.7    Publicity and Use of Marks. 

(a)    Publicity. Except as provided in Section 8.2(e), Aura may not publish or make known to others the
existence, terms, or subject matter of this Agreement without first obtaining the prior written approval of LI-COR; provided that, notwithstanding anything to the contrary, Aura may disclose or reference the
existence of this Agreement and the existence of its rights under Section 2.1, but no other terms of this Agreement. 

(b)    Use of Marks. Aura and its Affiliates and Sublicensees may not use the name
“LI-COR,” “LI-COR Biosciences” “IRDye,” “IRDye 700DX,” or any other mark of LI-COR
without the prior written consent from LI-COR, such consent not to be unreasonably withheld. 

5.8    Improvements. The Parties acknowledge and agree that LI-COR will own
any Improvements developed by Aura or its Affiliates or Sublicensees. Aura hereby assigns to LI-COR all right, title, and interest in and to such Improvements, and agrees to take all such actions, and execute
such documents, as LI-COR may request to secure title to such Improvements in LI-COR. Aura shall timely disclose to LI-COR each
Improvement, and further shall provide LI-COR all information concerning each such Improvement. All Improvements will automatically become licensed to Aura as part of the Licensed Patent or Know-How under this Agreement. 
 ARTICLE 6 

Supply of IRDye 700DX 

6.1    Supply & Exclusivity. Subject to Section 6.8, Aura, its
Affiliates and Sublicensees shall during the Term, on a country-by-country basis, purchase all of their requirements of IRDye 700DX exclusively from LI-COR. LI-COR shall manufacture and supply Aura, its Affiliates and Sublicensees with non-cGMP IRDye 700DX meeting the Forecast,
subject to the terms and conditions of this Agreement, and in accordance with the specifications (“Specifications”) set forth in Exhibit A. In the event Aura, its Affiliates or Sublicensees
require cGMP IRDye 700DX to manufacture Licensed Product, Aura, its Affiliates and Sublicensees shall obtain their requirements of such from LI-COR. The price for any cGMP IRDye 700DX supplied by LI-COR to Aura, its Affiliates or Sublicensees shall be reasonably determined by LI-COR. 

6.2    Forecasting. Commencing on the Effective Date, Aura shall provide LI-COR with a rolling, eighteen (18)
month forecast (“Forecast”) of anticipated quantities and order dates for IR Dye 700DX, with the first six (6) months of each Forecast binding upon Aura. Such Forecast will be updated and submitted monthly, and
will be sent by mail or email to [***] ([***]), LI-COR Biosciences, 4647 Superior Street, Lincoln, Nebraska 68504. 

  
 11 

 6.3    Orders and Acceptance. 

(a)    Orders. Aura shall place purchase orders for IRDye 700DX from time to time, provided that Aura shall at a
minimum place orders in accordance with the binding portion of the Forecast as set forth in Section 6.2 hereof. Each purchase order will specify: (a) the quantity of IRDye 700DX desired, which quantity shall not be less than
50 mg per purchase order; (b) the desired delivery date(s); and (c) the ship to address. No purchase order will be binding on the Parties unless and until accepted by
LI-COR. Aura may cancel any purchase order if notice of cancellation is received by LI- COR in advance of LI-COR’s
acceptance of such purchase order. 
 (b)    Acceptance. LI-COR shall use
commercially reasonable efforts to accept each purchase order if it can deliver the IRDye 700DX on or before the requested delivery date. Each delivery of IRDye 700DX shall be made from either concurrently manufactured IRDye 700DX or from the safety
stock maintained by LI-COR as required by Section 6.7 hereof. Aura shall notify LI-COR of its acceptance or rejection within [***] after receipt of each such
purchase order. Any notice of acceptance will include confirmation of the requested quantities, the delivery date, and the applicable prices. 

6.4    Pricing and Payment. 

(a)    IRDye 700DX Pricing. Aura, its Affiliates and Sublicensees shall pay
LI-COR the following prices for non-cGMP manufactured IR Dye 700DX: 

         [***] 

(b)    Price Increases. Commencing on January 1, 2015, the prices in subsection (a) may be
increased by LI-COR from time to time, but not more than once per calendar year, to reflect reasonable increases in LI-COR’s manufacturing and supply costs
(including materials costs). 
 (c)    Payment. Aura shall pay for each accepted and undisputed purchase order
within [***] after the date of LI-COR’s invoice for the same. 

6.5    Delivery. Deliveries of IRDye 700DX will be made on the date specified in the accepted purchase order;
provided that LI-COR will not be obligated to ship any IRDye 700DX if Aura (or any of its Affiliates or Sublicensees) is delinquent in any undisputed payment for (a) any previously shipped order or
(b) any Royalties, Milestone Payments, or other fees owed to LI-COR. The terms of delivery from LI-COR to Aura will be
“Ex-Works Incoterms 2010 (EXW)” LI-COR’s facility, and risk of loss and title will pass to Aura accordingly. 

6.6    Inspection and Rejection. 

(a)    Inspection and Rejection. Aura will have [***] after receipt of a shipment of IRDye 700DX to inspect such
product and notify LI-COR if any such product fails to meet 

  
 12 

 
applicable specifications. Failure of Aura to provide notice within the aforesaid [***] period will cause such shipment to be deemed accepted. In the event Aura timely rejects any shipment of
product, it shall promptly return such nonconforming shipment to LI-COR with a detailed explanation as to the reason(s) for nonconformance. Aura must immediately upon receipt of delivery store and maintain all
IRDye 700DX in accordance with LI-COR’s instructions and applicable Law; if Aura fails to so store and maintain such product, Aura will have no right to inspect (and reject) the same hereunder. 

(b)    Disputes. In the event any shipment of IRDye 700DX is timely and properly rejected by Aura and LI-COR agrees that the IRDye 700DX does not conform to the applicable Specifications, LI-COR shall send a replacement shipment of IRDye 700DX within [***], after its
determination that the IRDye 700DX does not conform to the applicable Specifications. If LI-COR disagrees as to whether or not the IRDye 700DX meets the Specifications, the Parties shall submit the IRDye 700DX
in question to an independent third party that has the capability of testing the IRDye 700DX to determine whether or not it complies with applicable Specifications. The losing Party will bear all costs and expenses related to such testing. 

6.7    Safety Stock. LI-COR shall, at all times during the Term, maintain a
minimum safety stock of the IRDye 700DX sufficient to meet at least eighteen (18) months demand based on Aura’s Forecast. 

6.8    Secondary Supplier. In the event that LI-COR fails to supply Aura
with IRDye 700DX meeting the Forecast for a period of six (6) consecutive months, and LI-COR is unable to meet the Forecast after such six (6) consecutive month period (“Supply
Failure”), Aura may secure a secondary supplier to supply Aura’s Forecasted requirements of IRDye 700DX from such secondary supplier for such period that LI-COR is unable to meet
Aura’s Forecasted requirements. LI-COR shall use best efforts to assist Aura in providing Know-How to such secondary supplier necessary to manufacture the IR Dye
700DX. In the event of a Supply Failure, and subject to the terms set forth in this Agreement, LI-COR shall grant to a secondary supplier a non-exclusive royalty-bearing
license under the Licensed Patent and Know-How to make and have made IRDye 700DX on behalf of Aura for the Licensed Product for the Licensed Field in the Territory. Such license shall be limited to the period
of such Supply Failure and shall extend after such Supply Failure, provided, that after such Supply Failure such secondary supplier may supply up to twenty percent (20%) of Aura’s requirements of IR Dye 700DX. 

ARTICLE 7 

Representations and Warranties 

7.1    Of Both Parties. Each Party hereby represents and warrants to the other as follows: 

(a)    Organization. Such Party is duly organized, validly existing, and in good standing under the laws of the
state or province of its incorporation. 
 (b)    Authority and Validity. Such Party has all requisite corporate
power and authority to execute, deliver, and perform its obligations under this Agreement and to 

  
 13 

 
consummate the transactions contemplated hereby. The execution, delivery, and performance by such Party of its obligations under this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly authorized by all necessary action required on the part of such Party, and no other proceedings on the part of such Party are necessary to authorize this Agreement or for such Party to perform its
obligations under this Agreement. This Agreement constitutes the lawful, valid, and legally binding obligation of such Party, enforceable in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, or similar laws affecting the enforcement of creditors’ rights generally and general equitable principles, regardless of whether such enforceability is considered in a proceeding at law or in equity. 

(c)    No Violation or Conflict. The execution, delivery, and performance of this Agreement and the transactions
contemplated hereby do not: (i) violate, conflict with, or result in the breach of any provision of the organizational documents of such Party; (ii) conflict with or violate any Law applicable to such Party or any of its assets,
properties, or businesses; or (iii) conflict with, result in any breach of, constitute a default (or event that with the giving of notice or lapse of time, or both, would become a default) under, require any consent which has not been
obtained under, or give to others any rights of termination, amendment, acceleration, suspension, revocation, or cancellation of, or result in the creation of any lien or encumbrance on any of the assets of such Party, pursuant to any note, bond,
mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise, or other instrument or arrangement to which such Party is a Party except, in the case of (iii), to the extent that such conflicts, breaches,
defaults or other matters would not adversely affect the ability of such Party to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement. 

(d)    Governmental Consents and Approvals. The execution, delivery, and performance of this Agreement by such
Party do not require any approval from a governmental authority that has not already been obtained, effected, or provided, except with respect to which the failure to so obtain or make could not reasonably be expected to have a material adverse
effect on the business, operations, properties, financial condition, assets or liabilities, results of operations or prospects of such Party or its ability to perform its obligations under this Agreement. 

(e)    Litigation. There are no actions by or against such Party pending before any governmental authority or, to
the knowledge of such Party, threatened to be brought by or before any governmental authority relating to the subject matter of this Agreement. There are no pending or, to the knowledge of such Party, threatened actions to which such Party is a
party (or threatened to be named as a party) to set aside, restrain, enjoin, or prevent the execution, delivery, or performance of this Agreement or the consummation of the transactions contemplated hereby by either Party. Such Party is not subject
to any order of a governmental authority (nor, to the knowledge of such Party, is there any such order threatened to be imposed by any governmental authority) relating to the subject matter of this Agreement. 

7.2    Of LI-COR. LI-COR represents
and warrants that it owns the Licensed Patent and Know-How free and clear, to its knowledge, of all ownership claims and has the freedom to practice and license all rights granted in Section 2.1 and to
enter into this Agreement. 

  
 14 

 7.3    Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS
ARTICLE 7, LI-COR MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITY WHATSOEVER WITH RESPECT TO AURA’S (OR ITS AFFILIATE’S OR
SUBLICENSEE’S) (A) USE OF THE LICENSED PATENTS, KNOW-HOW, OR IRDYE 700DX, ALL OF WHICH IS PROVIDED “AS IS,” OR (B) RESEARCH OF, DEVELOPMENT OF, USE OF, OFFERING FOR SALE OF,
SELLING, OR HAVING SOLD ANY LICENSED PRODUCT. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES (X) OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE OR (Y) WITH RESPECT TO THE PERFORMANCE, SAFETY,
EFFECTIVENESS, OR COMMERCIAL VIABILITY OF THE LICENSED PRODUCT OR IRDYE 700DX, AND LI-COR HEREBY DISCLAIMS ALL SUCH WARRANTIES. FURTHER, AURA MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND,
EXPRESS OR IMPLIED EXCEPT AS EXPRESSLY SET FORTH HEREIN. 
 ARTICLE 8 

Confidentiality 

8.1    Confidentiality. Each Party may disclose to the other Party certain Confidential Information in connection
with this Agreement. The recipient of such information shall maintain the Confidential Information as secret and confidential, such efforts to be no less than the degree of care employed by the recipient to preserve and safeguard its own
confidential information (but in no event less than a reasonable degree of care). Confidential Information of the other Party may not be used other than for the purposes of carrying out the Parties’ respective rights and obligations under this
Agreement, nor shall such information be disclosed or revealed to anyone except employees, advisors, consultants and representatives of the recipient who have a need to know the Confidential Information and who have each entered into a
confidentiality agreement with the recipient, under which such employees, advisors, consultants and representatives are required to maintain as confidential the confidential or proprietary information of the recipient. Such employees, advisors,
consultants and representatives must be advised by the recipient of the confidential nature of the Confidential Information and that the Confidential Information must be treated accordingly. The obligations in this Section 8.1 apply to
Aura’s Affiliates, as well as any Sublicensees. 
 8.2    Exceptions. The recipient’s obligations under
Section 8.1 will not extend to any part of the Confidential Information: 
 (a)    that can be demonstrated to have
been in the public domain or publicly known and readily available to the trade or the public prior to the date of the disclosure; 

(b)    that can be demonstrated, from the recipient’s written records, to have been in the recipient’s
possession; 
 (c)    that becomes part of the public domain or publicly known by publication or otherwise, not due to
any unauthorized act by the recipient or any Third Party; 

  
 15 

 (d)    that is demonstrated from the recipient’s written records to
have been developed by or for the receiving Party without reference to Confidential Information disclosed by the disclosing Party; or 

(e)    that is required to be disclosed by applicable Law; provided that the recipient notifies the other Party prior to
such disclosure and fully cooperates with the other Party in the event that the other Party elects to contest and avoid such disclosure. 

8.3    Unauthorized Disclosure. Each Party acknowledges and agrees that the Confidential Information of the other
Party constitutes proprietary information and trade secrets valuable to the other Party, and that the unauthorized use, loss, or disclosure of such Confidential Information may cause irreparable injury to the other Party, for which monetary damages
may not be a sufficient remedy, and that the other Party may be entitled, without waiving other rights or remedies, to obtain injunctive or equitable relief as may be deemed proper by a court of competent jurisdiction in the event of any actual or
threatened unauthorized use, loss, or disclosure. 
 8.4    Notification. Each Party shall notify the other Party
promptly upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information, and shall cooperate with the other Party in any reasonably requested fashion to assist the other Party to regain possession of such
Confidential Information and to prevent its further unauthorized use or disclosure. 
 8.5    Duration. This
Article 8 will survive termination or expiration of this Agreement and will continue for a period of [***] from the date of that termination or expiration. 

ARTICLE 9 
 Term and
Termination 
 9.1    Term. The term of this Agreement (“Term”) will commence on
the date of this Agreement and will continue, on a country-by-country basis, until the longer of (a) ten (10) years from the First Commercial Sale of a
Licensed Product in such country and (b) the last to expire Valid Claim in such country. Upon expiration of the license in a country, Aura shall have a fully paid license under Section 2.1 under the Know-How in such country. 
 9.2    Termination. This Agreement may be
terminated: 
 (a)    by either Party upon [***] prior written notice for any material breach by the other Party of this
Agreement that remains uncured (other than with respect to late payments, which must be cured within [***]) at the end of such [***] period; provided, however, that if the breach is of such a nature that it cannot be cured within [***], then the
cure period shall continue, upon reasonable request by the breaching party, for up to [***]. 
 (b)    by either Party
immediately in the event that the other Party files or has filed against it a petition for bankruptcy, makes an assignment for the benefit of creditors, has a receiver appointed for it or a substantial part of its assets, or otherwise takes
advantage of any Law designed for relief of debtors; 

  
 16 

 (c)    by LI-COR in the event of
any violation or breach of Section 5.5, without any notice or additional waiting periods; or 
 (d)    by either
Party upon [***] prior written notice, if Aura completely abandons the development of a nanoparticle product conjugated with a dye for the Licensed Field. 

9.3    Effect of Termination. In the event of any termination or expiration of this Agreement: 

(a)    The License will immediately terminate, and Aura will no longer have any rights under the Licensed Patent,
Improvements or Know-How to research, develop, make, have made, use, have used, sell or have sold any Licensed Product, IRDye 700DX, or to make any other use of the Licensed Patent or Know-How. Further, both Parties will be released from all obligations and duties imposed or assumed hereunder to the extent so terminated, except as expressly provided to the contrary in this Agreement; 

(b)    Each Party will cease all use of the other Party’s Confidential Information. Further, each Party shall
promptly return to the other Party all Confidential Information of the other Party in such Party’s possession except for one (1) copy which may be maintained in a secure location for archival purposes only; 

(c)    Aura shall assign (and hereby assigns) and deliver to LI-COR any and all
regulatory files it may have concerning IR Dye 700DX; 
 (d)    Termination will not affect LI-COR’s right to recover unpaid Royalties, fees, Milestone Payments, or other forms of financial compensation incurred prior to or on termination or expiration. Upon termination, Aura shall submit a final
royalty report to LI-COR, and any Royalties, fees, Milestone Payments, and other financial compensation due LI-COR will become immediately payable and shall be paid
concurrent with the submission of such final royalty report; and 
 (e)    Upon termination of this Agreement by Aura
pursuant to Section 9.2(a) due to a uncured material breach by LI-COR, Aura, its Affiliates and Sublicensees shall have the right to use, sell or have sold un-used inventory of Licensed Product in its
possession for a period of three (3) months subject to the terms and conditions set forth in this Agreement. All such sales by Aura, its Affiliates and Sublicensees shall be subject to the Royalty set forth in Section 3.2.

 (f)    The following Articles and Sections will survive any termination of this Agreement: Sections 3.4, 3.5,
3.6, 4.2, 5.3 (solely with respect to the right of reference), 5.8, and Article 8; Section 9.3; and Articles 10, 12, and 13. 

  
 17 

 ARTICLE 10 

Indemnification 

10.1    Indemnification. 

(a)    By LI-COR. LI-COR shall
indemnify, defend, and hold harmless Aura, its Affiliates and Sublicensees, and their respective officers, directors, shareholders, employees, agents, contractors, and personnel from and against any and all Losses arising out of, based on, or
incidental to any breach of LI-COR’s representations and warranties in Article 7, except with respect to Losses for which LI-COR is entitled to
indemnification under subsection (b). In no event shall LI-COR be obligated to indemnify, defend, or hold harmless Aura, its Affiliates and Sublicensees, and their respective officers, directors,
shareholders, employees, agents, contractors, and personnel arising out of any claim related to the manufacture of IRDye 700DX in accordance with the Specifications, including, but not limited to, the manufacture of IRDye 700DX under non-cGMP conditions. 
 (b)    By Aura. Aura shall indemnify, defend, and hold
harmless LI-COR, its Affiliates, and its and their respective officers, directors, shareholders, employees agents, contractors, and personnel from and against any and all Losses arising out of, based on, or
incidental to any: (i) the research, development, manufacture, marketing, promotion, advertising, transportation, handling, storage, distribution, or commercialization with respect to any Licensed Product, including product liability, except to
the extent such Losses result from LI-COR’s gross negligence or willful misconduct; (ii) the research, development, manufacture, transportation, handling, storage, distribution, or commercialization
with respect to IRDye 700DX, except to the extent such Losses result from LI-COR’s gross negligence or willful misconduct; (iii) the practice or use of any the Licensed Patent, Improvements or Know-How by Aura, any of its Affiliates, or any of its or their Sublicensees, except to the extent such claim results from a breach by LI-COR of its representations and
warranties in Section 7.1 or 7.2; and (iv) any breach of this Agreement by Aura. The obligation of Aura to indemnify, defend, and hold harmless will continue after, and will not be affected by, any assignment, transfer, or sublicensing of
rights to any Affiliate or Sublicensee. 
 10.2    Notice and Defense of Third-Party Claims. In the event of a
claim by a Party for indemnification under this Article, such indemnified Party shall give the indemnifying Party prompt notice of the claim and copies of all papers served upon or received by the indemnified Party relating thereto. The indemnifying
Party will have the right to control the defense of such claim and all negotiations for its settlement or compromise; provided that the indemnifying Party (a) will not have the right to bind the indemnified Party to any non-financial settlement, consent, or other agreement without the prior written consent of the indemnified Party, which consent may not be unreasonably withheld or delayed and (b) shall keep the
indemnified Party fully informed in all respects concerning the defense and negotiation of the claim(s). The indemnified Party shall provide reasonable assistance to the indemnifying Party, at the indemnifying Party’s expense, in connection
with the defense of any such claim. The indemnified Party shall have the right to participate in the defense of any such claim, at its expense. 

  
 18 

 ARTICLE 11 

Insurance 

11.1    Requirements. Aura shall, at its sole cost and expense, procure and maintain insurance policies as follows:

 (a)    From the date of this Agreement and for a reasonable period after the last and final sale of any Licensed
Product (whether by Aura or its Sublicensee), comprehensive general liability insurance in an amount not less than $[***] per incident and $[***] in the annual aggregate. Such comprehensive general liability insurance must provide (i) product
liability coverage and (ii) contractual liability coverage (covering, without limitation, Aura’s indemnification obligations under this Agreement), pending confirmation of binding approval of 10.1(a)(ii) by Aura’s insurer. 

(b)    During all clinical trials and for a reasonable period after such trials, clinical trial insurance with per subject
coverage of $[***] and total study coverage in aggregate of $[***]. 
 11.2    Other Obligations. Aura shall name
LI-COR as an additional insured in each policy obtained and maintained in accordance with Section 11.1. Further, upon LI-COR’s request, Aura shall
promptly furnish LI-COR with written evidence of all such insurance policies. Aura shall provide LI- COR with at least [***] prior written notice before the
cancellation, non-renewal, or material change in any insurance policy. If Aura fails to obtain an applicable replacement insurance provision with comparable coverage within such [***] period, LI-COR will have the right to terminate this Agreement at the end of such [***] period, without any notice or additional waiting periods and without liability of any kind or nature to Aura. 

11.3    Third-Party Requirements. Aura shall require its Affiliates and Sublicensees to maintain insurance in favor
of LI-COR. 
 ARTICLE 12 

Limitation of Liability 

IN NO EVENT WILL EITHER PARTY BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN
CONNECTION WITH THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THE FOREGOING LIMITATIONS WILL NOT APPLY WITH RESPECT TO (1) A PARTY’S BREACH OF ITS CONFIDENTIALITY
OBLIGATIONS HEREUNDER; (2) A PARTY’S INDEMNIFICATION OBLIGATIONS HEREUNDER AND ANY AND ALL AMOUNTS PAID IN CONNECTION THEREWITH; AND (3) A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. 

ARTICLE 13 

Miscellaneous 

13.1    Force Majeure. If either Party fails to fulfill its obligations hereunder (other than an obligation for the
payment of money), when such failure is due to an act of God, or other circumstances beyond its reasonable control, including fire, flood, civil commotion, riot, war (declared and undeclared), revolution, or embargoes, then said failure will be
excused for the duration of such event and for such a time thereafter as is reasonable to enable the Parties to resume performance under this Agreement; provided that in no event will such time extend for a period of more than [***]. 

  
 19 

 13.2    Governing Law and Forum. This Agreement will be governed
by and construed in accordance with the laws of the State of Delaware, excluding any choice of law rules. Any action arising under or relating to this Agreement shall be brought in the U.S. District Court for the District of Nebraska, and the
Parties hereby consent to jurisdiction in such forum for any such action. To the extent permitted by applicable Law, each Party irrevocably waives all right of trial by jury in any action regarding or relating to this Agreement. 

13.3    Assignment. Aura may not sell, assign, delegate, pledge, dispose of, or transfer this Agreement or any
rights or duties hereunder, by operation of law or otherwise, without the prior written consent of LI-COR provided however, that no such consent will be required to assign, transfer or dispose of this
Agreement or any rights hereunder to a successor in connection with a merger, consolidation, business combination, sale, so long as Aura is not the surviving entity and the successor in interest agrees in writing to be bound by all the terms and
conditions hereof prior to such assignment. No assignment or other transfer will release Aura from responsibility for the performance of any accrued obligation of it hereunder (including payment obligations). This Agreement will be binding upon and
enforceable against each Party’s successors and permitted assigns and transferees. 
 13.4    Merger. This
Agreement represents the entire agreement between the Parties with respect to the subject matter hereof and supersedes all previous proposals and arrangements, oral and written, relating to such subject matter, including the term sheet (and all
amendments thereto). 
 13.5    Notices. All notices, communications and deliveries under this Agreement shall be
made in writing signed by or on behalf of the Party making the same, shall, as applicable, specify the Section under this Agreement pursuant to which it is given or being made, and shall be delivered personally or sent by registered or certified
mail (return receipt requested) or by overnight delivery (with evidence of delivery and postage and other fees prepaid) as follows: 
  

			
	If to LI-COR: 
LI-COR, Inc. 
ATTN: 
Title: 
4647 Superior Street 
Lincoln, NE 68504 
Phone: 
Email:	 	If to Aura: 
Aura Biosciences, Inc. 
ATTN: 
Title: 
85 Bolton Street 
Cambridge, MA 02140 
Phone: 
Email:
		
	With a copy to: 
[***]	 	With a copy to: 
Rubin and Rudman LLP 
ATTN: Peter B. Finn, Esq. 
50 Rowes Wharf 
Boston, MA 02110 
Phone: [***] 
Email: [***]

  
 20 

 13.6    General Interpretive Provisions. 

(a)    The words “hereof,” “herein,” “hereunder,” and similar words refer to this Agreement
as a whole and not to any particular provision of this Agreement. 
 (b)    The term “including” (and
variations thereof) is not limiting and means “including without limitation.” 
 (c)    The captions and
headings of this Agreement are for convenience of reference only and will not affect the interpretation of this Agreement. 

13.7    Severability. In the event a court of competent jurisdiction finds any provision herein illegal, invalid,
or unenforceable, that provision shall be enforced, if possible, to the greatest extent allowed by law in accordance with the Parties’ intent as reflected by this Agreement. If that provision cannot be enforced, the remainder of this Agreement
will be enforced to the greatest extent possible, and the offending provision will be treated as though not part of this Agreement. 

13.8    Amendments. This Agreement may not be amended or modified except by an instrument in writing signed by duly
authorized representatives of each Party. 
 13.9    Waivers. The failure of either Party to enforce at
any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision, nor in any way affect the validity of this Agreement or any part of it or the right of either Party after any such failure to enforce
each and every such provision. No waiver of any breach of this Agreement will be held to be a waiver of any other or subsequent breach. 

13.10    Counterparts. This Agreement may be executed in multiple counterparts, each of which will be deemed to be
an original and binding upon the Party who executed the same, but all of which together will constitute one and the same Agreement. 

13.11    Independent Contractors. The relationship between the Parties is and shall be that of independent
contractors. This Agreement does not establish or create a partnership or joint venture between the Parties. Neither Party shall have any right or authority to bind, or enter into any contract on behalf of, the other Party, nor shall either Party
hold itself out as having such authority. 
 13.12    Third-Party Beneficiaries. Nothing expressed or implied in
this Agreement is intended, or shall be construed, to confer upon or give any person or entity (including any client, customer, employee, partner or other representative of the Parties) other than the Parties and their successors or permitted
assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, or result in such person or entity being deemed a third party beneficiary of this Agreement. All provisions hereof shall be personal solely among the
Parties to this Agreement. 
 13.13    Construction. This Agreement has been negotiated by the Parties and their
respective counsel in good faith and will be fairly interpreted in accordance with its terms and without any strict construction in favor of or against any Party. 

  
 21 

 13.14    Export Controls. Each Party acknowledges that it is
subject to United States laws and regulations controlling the export of compounds, technical data, and other commodities, and that Aura’s rights under this Agreement are contingent on compliance with applicable United States export laws and
regulations. The transfer of certain technical data and commodities may require a license from an applicable agency of the United States government and written assurances by Aura that Aura shall not export data or commodities outside of the United
States without prior approval of such agency. Aura shall take all actions necessary to insure compliance with all such laws and regulations, orders or other restrictions on exports and further will not sell, license or
re-export directly, or indirectly, the Licensed Product to any Person for use in any country or territory if such license or use would cause Aura or LI-COR to be in violation of such laws or regulations now or
hereafter in effect. 
 13.15    US Dollars. All payment hereunder shall be made in United States Dollars. 

13.16    Further Assurances. Each Party shall, at the reasonable request of the other Party, execute and deliver to
the other such instruments and documents and shall take such actions as may be required to more effectively carry out the terms of this Agreement. 

13.17    Dispute Resolution. In the event of any dispute, controversy, disagreement, breach or claim arising out of
or relating to this Agreement or interpretation of any of the provisions (“Dispute”), such Dispute shall be submitted for resolution in accordance with the following procedures: 

(a)    The Parties initially shall attempt to settle any Dispute through good faith negotiations between representatives
from each Party in the spirit of mutual cooperation. If the representatives are unable to resolve such Dispute within [***], the Parties shall submit such Dispute to the Parties respective Executive Officers (the “Executives”)
for good faith discussion and attempted resolution. If the Executives are unable to resolve such Dispute within [***], then for such Dispute shall be settled by final and binding, non-appealable
arbitration pursuant to Section 13.17(b). 
 (b)    If the Dispute has not been satisfactorily resolved (or
waived) pursuant to Section 13.17(a), then the matter shall be referred to arbitration for resolution under the then commercial arbitration rules of the American Arbitration Association (the “A.A.A.”) and the decision of the
arbitrators shall be final and binding on the parties. Unless the Parties agree otherwise, the number of arbitrators shall be three, and all three shall be independent, neutral, and experienced in the biotechnology industry. One such arbitrator
shall be appointed by each Party within [***] of the initiation of arbitration under this Agreement, and the third such arbitrator shall be selected by mutual agreement of the two such arbitrators selected by the Parties. To the extent three such
arbitrators are not selected within [***] of the initiation of arbitration hereunder, such arbitrators shall be appointed by the A.A.A. Each Party shall be responsible for the filing fee and the arbitrator’s fee; and otherwise, each Party shall
be responsible for its own costs and expenses, including but not limited to, travel, consultants, depositions, witnesses and attorneys’ fees and disbursements. The arbitrators shall be authorized to only interpret and apply the provisions of
this Agreement or any related agreements entered into under this Agreement and shall have no power or authority to modify or change any of the above in any manner. The arbitrators shall have no authority to award punitive or speculative

  
 22 

 
damages or any damages inconsistent with the Agreement. In addition to any monetary award, the arbitrators shall be empowered to award equitable relief, including an injunction and specific
performance of any obligation under this Agreement. The arbitrators shall, within [***] of the conclusion of the hearing, unless such time is extended by mutual agreement, notify the parties in writing of the decision, stating the reasons for such
decision and separately listing the findings of fact and conclusions of law. The arbitration shall be conducted in Chicago, Illinois and shall be governed by the laws of the State of Delaware, and the decision of the arbitrators may be entered in
any court of competent jurisdiction. The arbitration proceedings and the decision of the arbitrators will be kept confidential by the Parties and the arbitrators. 

//SIGNATURE PAGE FOLLOWS// 

  
 23 

 The Parties are signing this License and Supply Agreement on the date stated in the
introductory clause. 
  

							
	LI-COR, INC.	 	AURA BIOSCIENCES, INC.
				
	 By:
	 	 /s/ [***] 

	 	By:	 	 /s/ Elisabet de los Pinos 

	Name: [***] 
Title: [***]	 	Name: Elisabet de los Pinos, Ph. D. 
Title: President and CEO

  
 24 

 Exhibit A 

SPECIFICATIONS 
 [***] 

  
 25 

 AMENDMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

This Amendment to the Exclusive License and Supply Agreement (the “Amendment”) is entered into as of January 26,
2016 (the “Effective Date”), by and between LI-COR, Inc., a Nebraska corporation with a principal address of 4647 Superior Street, Lincoln, Nebraska 68504 (“LI-COR”), and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (“Aura”). All defined terms used herein, but not
defined, shall have the meanings ascribed to such terms in the Agreement (as defined below). 
 WHEREAS, the Parties entered into that
certain Exclusive License and Supply Agreement, dated as of January 31, 2014 (the “Agreement”); 
 WHEREAS, the
Agreement set forth a procedure whereby Aura was granted a limited right and option to extend any Achievement Date for a Diligence Event by six (6) month increments by making a ten thousand dollar payment for each such extension; 

WHEREAS, Aura has inter alia requested an extension of two (2) Achievement Dates associated with certain Diligence Events; 

WHEREAS, the Parties desire to amend the Agreement to reflect the foregoing. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be
legally bound, hereby agree as follows: 
 1.    Amendments. 

1.1    Section 1.15 of the Agreement is hereby amended and replaced in its entirely as follows: 

““Licensed Product” means tumor binding or tumor targeting molecules (excluding antibodies, antibody fragments and
antibody-like constructs) conjugated with IRDye 700DX.” 
 1.2    Section 5.1(b) of the Agreement is hereby
amended and replaced in its entirely as follows: 
 “Key Diligence Obligations. Aura shall use Commercially Reasonable Efforts to
achieve each of the following diligence events (each , a “Diligence Event”) by the corresponding achievement date set forth below (“Achievement Date”). Notwithstanding the foregoing, Aura shall have the right
and option to extend any Achievement Date for a Diligence Event by six (6) month increments (but not more than two (2) times with respect to first and second Diligence Events, and not more than three (3) times with respect to the
third, fourth, and fifth Diligence Events) by making a [***] payment to LI-COR prior to the expiration of the Achievement Date for such Diligence Event. In the event that Aura extends an Achievement Date for a
Diligence Event, the Achievement Dates for the remaining Diligence Events subsequent to such extended Achievement Date shall also be extended by six (6) month increments at no additional cost. 

					
	 	 	 Diligence Event
	  	Achievement
Date
	 1.
	 	[***]	  	[***]
	 2.
	 	[***]	  	[***]
	 3.
	 	[***]	  	[***]
	 4.
	 	[***]	  	[***]
	 5.
	 	[***]	  	[***]

 In the event that Aura fails to achieve any Diligence Event by the applicable Achievement Date, and Aura does
not elect to extend the applicable Achievement Date as permitted by this Section 5.1(b), then this License shall automatically convert to a non-exclusive license.” 

2.    Payments. Aura shall pay LI-COR as follows: 

2.1    As partial consideration for the rights granted to Aura pursuant to Section 1.1 of this Amendment, Aura shall
pay LI-COR: 
 (a)    a one-time, non-refundable, non-creditable payment in the amount of [***], and 

(b)    a one-time, non-refundable, non-creditable payment in the amount of [***]. 
 2.2    As partial consideration for
the rights granted to Aura pursuant to Section 1.2 of this Amendment, upon the Effective Date, Aura shall pay LI-COR a one-time,
non-refundable, non-creditable payment in the amount of [***]. 

3.    License. The Parties acknowledge and agree that, notwithstanding the fact that Aura failed to achieve its first Diligence
Event by the applicable Achievement Date under the Agreement, and did not elect to extend such Achievement Date prior to such date, the License did not automatically convert to a non-exclusive license. 

4.    General Provisions. 

4.1    All other terms and conditions of the Agreement shall remain in full force and effect. 

4.2    The captions to the paragraphs/sections in this Amendment are not a part of this Amendment or the Agreement, and
are included merely for convenience of reference only and shall not affect its meaning or interpretation. 

 4.3    This Amendment was drafted by all Parties concerned and thus any
rule of contract interpretation calling for documents to be construed against the drafter shall not apply to the construction of this Amendment. 

4.4    This Amendment, together with the Agreement, constitutes the entire agreement between the Parties with respect to
the subject matter hereof. In the event of a conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall prevail. 

[Signature page follows] 

 IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this
Amendment as of the Effective Date. 
  

									
	LI-COR, INC.	 		 	AURA BIOSCIENCES, INC.
					
	By:	 	 /s/ ***
	 		 	By:	 	 /s/ Elisabet de los Pinos

	 Name: ***
 Title: ***
	 		 	 Name: Elisabet de los Pinos, Ph. D.

Title: President and CEO

 AMENDMENT 2 TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

This Amendment 2 to the Exclusive License and Supply Agreement (the “Amendment”) is entered into as of
July 27, 201 7 (the “Effective Date”), by and between LI-COR, Inc., a Nebraska corporation with a principal address of 4647 Superior Street, Lincoln, Nebraska 68504 (“LI-COR”), and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (“Aura”). All defined terms used herein, but not
defined, shall have the meanings ascribed to such terms in the Agreement (as defined below). 
 WHEREAS, the Parties entered into that
certain Exclusive License and Supply Agreement, dated as of January 31, 2014 (the “Agreement”); and further amended January 26, 2016; 

WHEREAS, the Parties have requested clarification on several definitions in the Agreement: 

WHEREAS, LI-COR has agreed to provide Aura with an additional product under the Agreement; 

WHEREAS, LI-COR has requested Aura to assist with patent term extension under the Agreement; and
WHEREAS, pursuant to Section 13.8 of the Agreement, the Parties desire to amend the Agreement to reflect the foregoing. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 

1.      Amendments. 

1.1    Section 1.10 is deleted and is hereby amended and replaced with: 

“1.10 “IRDye 700DX” means IRDye 700DX Carboxylate and any components, fragments, modifications, or derivatives of such
dye (“IRDye 700DX Carboxylate”) and any precursors of IRDye 700DX Carboxylate, such as IRDye 700DX Step D, as set forth in Exhibit B.’’ 

1.2    Section 1.22 is deleted and is hereby amended and replaced with: 

“1.22 “Pivotal Clinical Trial” means a clinical study on a sufficient number of subjects that is designed to establish that a
Licensed Product is safe and efficacious for its intended use and to determine warnings, precautions and adverse reactions that are associated with such Licensed Product in the dosage range to be prescribed, as more fully defined in 21 C.F.R.
§312.21(c), as amended, such clinical study which is intended to support Regulatory Approval of such Licensed Product, including all tests and studies that are required by the FDA from time to time, pursuant to Applicable Law or otherwise an
expanded human clinical trial intended to gather information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship and to provide an adequate basis for physician labeling.” 

 1.3    Each reference in the Agreement to the term “Phase III
Clinical Trial is hereby deleted and replaced with the term “Pivotal Clinical Trial.’’ 
 1.4    The last
sentence of Section 2.1 is deleted and is hereby amended and replaced with: 
 “Notwithstanding the foregoing, such
License does not include the right to make or have made IRDye 700DX, other than modification of the IRDye 700DX Step D to perform the carboxylate processing of such IRDye 700DX Step D to make IRDye 700DX Carboxylate.’’ 

1.5    Section 5.1 (b) is hereby deleted and replaced in its entirety as follows: 

“(b) Key Diligence Obligations. Aura shall use Commercially Reasonable Efforts to achieve each of the following
diligence events (each, a “Diligence Event”) by the corresponding achievement date set forth below (“Achievement Date”). Notwithstanding the foregoing, Aura shall have the right and option to extend any
Achievement Date for a Diligence Event by six (6) months increments, but not more than three (3) times per Diligence Event, by making a [***] payment to LI-COR prior to the expiration of the
Achievement Date for such Diligence Event. 
  

					
	 	 	Diligence Event	  	Achievement
Date
	 1.
	 	[***]	  	[***]
	 2.
	 	[***]	  	[***]
	 3.
	 	[***]	  	[***]
	 4.
	 	[***]	  	[***]
	 5.
	 	[***]	  	[***]

 (i) In the event that Aura fails to meet the Achievement Date for one or more of Diligence Events 3, 4 or
5 referenced in the table above, then Aura shall by obligated to pay LI-COR as follows (each, a “Failure Payment”): 
  

	 	A.	 Failure to meet the Achievement Date for Diligence Event 3 or 4: Payment of the $[***] associated with
successful completion of the first Pivotal Clinical Trial with a NDA accepted by the FDA, as set forth in Section 3.3. 

  

	 	B.	 Failure to meet the Achievement Date for Diligence Event 5: Payment of the $[***] associated with the first
Commercial Sale of Licensed Product for clinical (non-research) human in vivo use in the United States, as set forth in Section 3.3. 

Aura shall also provide a reasonably detailed written report demonstrating Aura’s use of its Commercially Reasonable Efforts to achieve
the Diligence Event, and upon receipt of such report and Failure Payment for such Diligence Event, Aura shall be deemed by LI-

 
COR to have met all requirements associated with such Diligence Event. In addition, the full payment of a Failure Payment by Aura shall satisfy the applicable Milestone Payment in
Section 3.3 and no additional payments shall be due to LI-COR for the achievement of that Milestone. 

(ii)    In the event that Aura fails to achieve any Diligence Event by the applicable Achievement Date, and Aura has not
elected to either extend the applicable Achievement Date as permitted by this Section 5.1 (b) and has not elected to proceed according to the provision in Section 5.1(b)(i), then this License shall automatically convert to a
nonexclusive license.” 
 1.6    To clearly identify the appropriate Drug Master File, the first sentence of
Section 5.3(b) is deleted and is hereby amended and replaced as follows: 
 “(b) By
LI-COR. LI-COR will provide Aura with a right to reference LI-COR’s DMF for IRDye 700DX Carboxylate.” 

1.7    Section 5.6 is hereby amended to include, after the last sentence in Section 5.6, the following sentence:

 “Notwithstanding the foregoing, regulatory requirements for labeling and packaging in a region may overrule such requirement for Aura
to prominently display the LI-COR name or patent information pertaining to the Licensed Product.” 

1.8    New Section 5.9 is hereby added immediately after Section 5.8 as follows: 

“5.9 Patent Term Extension. The Parties shall reasonably cooperate with each other in obtaining patent term extension in any
country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. § 156, where applicable to the Licensed Patents. If any election with respect to seeking such patent term extension is to be made in any country in the
Territory with respect to the Licensed Patents, then LI-COR, in its sole discretion, shall make such election (including by filing supplementary protection certificates and any other extensions that are now or
in the future become available). Aura shall abide by such election and cooperate, as reasonably requested by LI-COR, in connection with the foregoing (including by providing appropriate information and
executing appropriate documents).” 
 1.9    The last sentence of Section 6.2 is deleted and is hereby amended
and replaced with: 
 “Such Forecast will be updated and submitted quarterly, and will be sent by mail or email to [***] ([***]), LI-COR Biosciences, 4647 Superior Street, Lincoln, Nebraska 68504.” 

1.10    Section 6.3 is hereby amended and replaced in its entirety as follows: 

“(a) Orders. Aura shall place purchase orders for IRDye 700DX from time to time, provided that it shall at a minimum place orders
in accordance with the binding portion of the Forecast. Each purchase order will specify: (a) the description of the product; (b) part number; 

 
(c) the quantity of IRDye 700DX desired, which quantity shall not be less than 50 mg per purchase order; (d) the desired delivery date(s); and (e) the ship to address. No
purchase order will be binding on (he Parties unless and until accepted by LI-COR. Aura may cancel any purchase order if notice of cancellation is received by LI-COR in
advance of LI-COR’s acceptance of such purchase order. 
 (b) Acceptance. LI-COR shall use Commercially Reasonable Efforts to accept each purchase order if it can deliver the IRDye 700DX on or before the requested delivery date, and shall notify Aura of its acceptance or rejection within
[***] after receipt of each such purchase order. Any notice of acceptance will include confirmation of the requested quantities, the delivery date, and the applicable prices. If the order from Aura requires more than one batch or lot of material to
fulfill said order, LI-COR shall consult with Aura as to how to proceed.” 

1.11    Section 6.4(a) is hereby amended and replaced in its entirety as follows: 

“(a) IRDye 700DX Pricing. Aura, its Affiliates and Sublicensees shall pay LI-COR in
accordance with the following: 
 [***] 

1.12    Section 10.1(b)(ii) is hereby amended and restated as follows: 

“(ii) the research, development, manufacture, transportation, handling, storage, distribution, or commercialization with respect to IRDye
700DX and any modification of the IRDye 700DX Step D by Aura, its Affiliates or Sublicensees, except to the extent such Losses result from LI-COR’s gross negligence or willful misconduct;’’ 

1.13    To include the specifications for non-GMP IRDye 700DX Carboxylate and IRDye
700DX Step D, Exhibit A (Specifications) of the Agreement is hereby amended and replaced in its entirety with Exhibit A attached hereto. 

1.14    New Exhibit B (IRDye 700DX) attached hereto, is hereby added immediately after Exhibit A (Specifications) to
the Agreement. 
 2.    General Provisions. 

2.1    All other terms and conditions of the Agreement shall remain in full force and effect. 

2.2    The captions to the paragraphs/sections in this Amendment are not a part of this Amendment or the Agreement, and
are included merely for convenience of reference only and shall not affect its meaning or interpretation. 
 2.3    This
Amendment was drafted by all Parties concerned and thus any rule of contract interpretation calling for documents to be construed against the drafter shall not apply to the construction of this Amendment. 

 2.4    This Amendment, together with the Agreement, constitutes the
entire agreement between the Parties with respect to the subject matter hereof. In the event of a conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall prevail. 

2.5    This Amendment may be executed in any number of counterparts, each of which shall be an original as against either
Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. An executed facsimile or electronic copy of this Amendment shall have the same force and effect as an original. 

IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this Amendment as of the Effective Date. 

 

									
	LI-COR, INC.	 		 	AURA BIOSCIENCES, INC.
					
	By:	 	 /s/ [***]
	 		 	By:	 	 /s/ Elisabet de los Pinos

	 Name: [***]
 Title: [***]
	 		 	 Name:

Title:

 Exhibit A 

Specifications 
 [***] 

 Exhibit B 

IRDye 700DX 
 [***] 

 

 
 AMENDMENT NO. 3 TO 

LICENSE AND SUPPLY AGREEMENT 

This Amendment No. 3 to License and Supply Agreement (“Amendment”) is entered into on April 2018, (the
“Amendment Effective Date”) by and between LI-COR, INC. (D/B/A LI-COR BIOSCIENCES), a Nebraska corporation with a principal address of
4647 Superior Street, Lincoln, Nebraska 68504 (“LI-COR”), and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140
(“Aura”). 
 WHEREAS, LI-COR and Aura have entered into a License and Supply
Agreement dated January 31, 2014, and amended January 26, 2016, further amended July 27, 2017 (the “Agreement”). 

WHEREAS, the parties now wish to amend the Agreement to reduce the pricing for IRDye 700DX. 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants, representations and warranties set forth herein,
the parties agree as follows: 
 SECTION 1.    Definitions; References. Unless otherwise
specifically defined herein, each term used herein which is defined in the Agreement shall have the meaning assigned to such term in the Agreement. 

SECTION 2.    Amendment of Section 6.4(a). Section 6.4(a) of
the Agreement is hereby amended and replaced in its entirety as to read as follows: 
 “6.4 IRDye 700DX Pricing. Aura, its
Affiliates, and Sublicensees shall pay LI-COR the following priced for non-cGMP manufactured IRDye 700DX: 

 

									
	 Lifetime quantity
	  	Non-GMP IRDye
700DX Carboxylate
“Step D” Pricing
per gram	 	 	Non-GMP IRDye
700DX
Carboxylate 
“Step F” Pricing
per gram	 
	 [***]
	  	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 

 SECTION 11.    Construction of Agreement. Except as amended and
supplemented hereby, all of the terms of the Agreement are incorporated herein by reference and shall remain and continue in full force and effect and are hereby ratified and confirmed in all respects. 

 IN WITNESS WHEREOF, the parties have hereto caused their duly authorized
representatives to execute this Amendment as of the date first written above. 
  

							
	LI-COR, INC.	  	AURA BIOSCIENCES, INC.
				
	By:	 	 /s/ [***]

[***]
 [***]
	  	By:	 	 /s/ Elisabet de los Pinos

				
	Date:	 	 4-15-18
	  	Date:	 	 4-30-18

 AMENDMENT 4 TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

This Amendment 4 (this “Amendment”) to the Exclusive License and Supply Agreement described below is entered into
as of April 2, 2019 (the “Effective Date”), by and between LI-COR, Inc., a Nebraska corporation with a principal address of 4647 Superior Street, Lincoln, Nebraska 68504
(“LI-COR”), and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (“Aura”). All defined terms used
herein, but not defined, shall have the meanings ascribed to such terms in the Agreement (as defined below). 
 WHEREAS, the Parties entered
into that certain Exclusive License and Supply Agreement, dated as of January 31, 2014 (the “Agreement”); and further amended January 26, 2016, July 27, 2017 and April 12, 2018; 

WHEREAS, the Parties have requested clarification on certain definitions and terms in the Agreement; 

WHEREAS, pursuant to Section 13.8 of the Agreement, the Parties desire to amend the Agreement to reflect the foregoing. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be
legally bound, hereby agree as follows: 
  

	1.	 Amendments. 

1.1    Section 1.13 is deleted and is hereby amended and replaced with: 

“1.13 “Licensed Field” means use in the treatment and diagnosis of ocular cancer, including ocular pre-cancer and indeterminate lesions.” 
 1.2    Section 13.3 is amended by
deleting the phrase “so long as Aura is not the surviving entity” and inserting in its place the phrase “so long as Aura is the surviving entity”. 
  

	2.	 General Provisions. 

2.1    All other terms and conditions of the Agreement shall remain in full force and effect. 

2.2    The captions to the paragraphs/sections in this Amendment are not a part of this Amendment or the Agreement, and
are included merely for convenience of reference only and shall not affect its meaning or interpretation. 
 2.3    This
Amendment was drafted by all Parties concerned and thus any rule of contract interpretation calling for documents to be construed against the drafter shall not apply to the construction of this Amendment. 

 2.4    This Amendment, together with the Agreement, constitutes the
entire agreement between the Parties with respect to the subject matter hereof. In the event of a conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall prevail. 

2.5    This Amendment may be executed in any number of counterparts, each of which shall be an original as against either
Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. An executed facsimile or electronic copy of this Amendment shall have the same force and effect as an original. 

IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this Amendment as of the Effective Date. 

 

							
	LI-COR, INC.	  	AURA BIOSCIENCES, INC.
				
	By:	 	 /s/ [***]
	  	By:	 	 /s/ Elisabet de los Pinos

		 	 [***]
 [***] 
4/5/2019
	  	Name: Elisabet de Pinos
 Title: President and CEO

4/5/2019

 

 
 LI-COR, Inc. 

4647 Superior Street 
 Lincoln,
Nebraska 
 68504 USA 
 Phone:
[***] 
 Toll Free U.S. & Canada: [***] 

www.licor.com 
 Email 

June 5, 2020 
 Elisabet de los Pinos, CEO 

Aura Biosciences, Inc. 
 85 Bolton Street 

Cambridge, MA 02140 
  

	Re:	 Exclusive License Agreement Between Aura Biosciences and LI-COR dated
January 31, 2014 (the “Agreement”); LI-COR Agreement #2013-154 

Dear Elisabet, 
 As mutually agreed between Aura Biosciences and
LI-COR, Aura Biosciences shall pay LI-COR [***] ($[***])] on or before June 30, 2020 and [***] ($[***])] on or before May 1, 2021 as Failure Payments under
Section 5.1(b)(i)A and B of the Agreement. The timely receipt of the foregoing Failure Payments by LI-COR shall satisfy Aura’s obligations under the terms of Section 5.1(b)(i) A and B of the
Agreement and no breach of the Agreement will have occurred on behalf of Aura, provided that Aura Bioscience remains in compliance of Section 5.1(a) and the Agreement shall remain an exclusive Agreement unless Aura fails to timely pay the
Failure Payments. 
 Sincerely, 
 /s/ [***] 

[***] 
 [***] 

 

	
	Agreed and Accepted by Aura Biosciences
	
	 /s/ Elisabet de los Pinos

	 Elisabet de los Pinos
 CEO

 
 6/5/2020

	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]